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Introduction 
 
This dissertation is submitted as a cumulative thesis according to the doctoral 
degree regulations of the Faculty of Medicine of the Justus-Liebig-University of 
Giessen. The thesis includes an interconnection of three original papers. 
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2. Introduction 
 
2.1 Protein tyrosine phosphatase interacting protein 51 
2.1.1 Background 
The protein tyrosine phosphatase interacting protein 51 (PTPIP51) was detected 12 
years ago by yeast two-hybrid screens used for the identification of potential 
substrates of the non-receptor tyrosine phosphatases TcellPTP and PTP1B 
(PTP1B) (Porsche et al, 2001). Up to date, the protein PTPIP51 as well as its gene 
is discussed in the literature under different synonyms. The gene is also known as 
FAM82A2, FAM82C, hucep-10, RMD3, hRMD-3, FLJ10579, LOC55177 or ptpip51. 
Aside from the name PTPIP51, the protein has also been described as cerebral 
protein 10, TCPTP-interacting protein 51, microtubule-associated protein, regulator 
of microtubule dynamics 3, family with gene sequence similarity 82, FAM82C or 
FAM82A2 (Brobeil et al, 2011a). 
 
 
Figure 1: The PTPIP51 gene location on chromosome 15q15.1 (Stenzinger et al 
2009) 
 
In humans the PTPIP51 gene is located in chromosome 15 (15q15.1.) [Figure 1]. It 
comprises 13 exons, of which exons 2-13 are encoding. The whole gene including 
the non-coding exon has a length of 19.373 basepairs. The full-length sequence 
encodes a protein of 470 amino acids with a molecular weight of 52,118 kDa 
(Stenzinger et al, 2009). The protein is phosphorylated in vitro and in situ at Tyr 176 
by Src kinase and dephosphorylated by PTP1B (Stenzinger at al 2009). The 
PTPIP51 protein has a N-terminal transmembrane domain required for its 
association with membranes, eg to mitochondria. If overexpressed in HeLa and 
HEK293T cells, mitochondria associated PTPIP51 induces apoptosis (Lv et al, 
2006).  
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Beside the full length form of 52 kDa, there exist several smaller isoforms of 
PTPIP51 being expressed in different tissues and cells. These isoforms with 
molecular weights of 45 kDa, 38 kDa and 30 kDa can be explained by alternative 
initiation codons (Kozak sequences), which give rise to these molecular weight 
forms (Stenzinger et al, 2009, Brobeil et al 2011a). In addition to these forms, there 
are further isoforms of shorter length and lower molecular weight, which can not be 
explained by leaky scanning and are probably the result of alternative splicing. The 
higher molecular weight forms (75 kDa, 65 kDa and 60 kDa) are posttranslationally 
modified forms. These variants may explain the different localizations and functions 
seen for PTPIP51 in different tissues. 
PTPIP51 is involved in many different processes. Brobeil and coworkers (2012) 
described its involvement mitogenic processes (Brobeil et al, 2012b). Mitosis is 
characterized by four stages: prophase, anaphase, metaphase and telophase (Yao 
et al, 2012). The mitotic processes are controlled by various checkpoints and there 
are certain signalling pathways needed for entering mitosis. As Brobeil and 
coworkers (2012b) demonstrated, PTPIP51 is located at the equatorial region during 
mitosis, building a PTPIP51/CGI-99 and a PTPIP51/Nuf-2 complex for correct 
chromosome segregation by the spindle apparatus. The mitogen activated protein 
kinase (MAPK) pathway plays a critical role in the G2/M transition (Hayne et al, 
2000).  PTPIP51 interacts with Raf-1 through the scaffolding protein 14-3-3β and 
thereby stimulating the MAPK cascade (Yu et al, 2008), thus probably regulating 
G2/M transition [Figure 2]. There are numerous interaction partners linking PTPIP51 
to a number of signalling pathways other than the MAPK way. By the diversity of 
interactions PTPIP51 can regulate and intervene in different processes such as 
proliferation, differentiation, apoptosis and migration. 
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Figure 2: PTPIP51 interacting with 14-3-3β and Raf-1 when dephosphorylated by 
PTP1B. The complex of PTPIP51, 14-3-3β and Raf-1 stimulates the EGFR/MAPK 
pathway. The Hedgehog pathway stimulates MAPK, PTPIP51 interaction with Gli is 
part of this pathway. PTPIP51 influences calcium homeostasis by interaction with 
VAPB, which links the endoplasmic reticulum to mitochondria in neuronal cells. 
During mitosis PTPIP51 is located in equatorial region, building a PTPIP51/CGI-99 
and a PTPIP51/Nuf-2 complex for correct chromosome segregation by the spindle 
apparatus. 
 
2.1.2 PTPIP51 tissue expression 
Interestingly, PTPIP51 shows specific expression profiles in numerous tissues. It is 
expressed in different developmental stages of placenta, here in different cell types 
(Stenzinger et al, 2009), in embryonic tissue e.g. during the development of the eye 
(Märker et al, 2008), in developing and adult skeletal muscle associated to the type 
IIa fibers (Barop et al, 2009), in epidermis (Pfeiffer, doctoral thesis, JLU, 2006), in fat 
tissue (Bobrich et al, 2011) and in diverse types of cells of the blood (Brobeil et al, 
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2010, 2011b). There was a high expression of PTPIP51 in peripheral nerve fibres 
and in the ganglia of the autonomous nerve system as identified by co-expression of 
the neuronal marker PGP9.5 (Koch et al, 2009b). Studies of PTPIP51 in mouse 
brain revealed its expression to be restricted to neurons, whereas there was no 
expression of PTPIP51 in glial cells (Koch et al, 2009a). 
Many studies confirmed the expression of PTPIP51 mRNA in human tissues e.g. 
kidney, liver, lung, pancreas, spleen, skeletal muscle, cerebrum, cerebellum and 
fetal brain (Stenzinger et al 2005, 2007,2009; Lv et al 2006; Barop et al 2009; Koch 
et al 2009a; Brobeil et al 2010). 
 
 
2.1.3 Expression of PTPIP51 in human carcinoma 
Aside from the expression of PTPIP51 in healthy tissue, Lv et al (2006) detected 
PTPIP51 mRNA in many human carcinoma cell lines representing bladder, 
esophagus, liver, lung, kidney, rectum and stomach carcinoma. In situ expression of 
PTPIP51 is also seen in various human carcinomas. In acute myeloid leukemia 
(AML) represents a non-solid tumour. The AML blasts express PTPIP51 (Brobeil et 
al, 2011b). Likewise PTPIP51 is expressed in human keratinocyte carcinoma such 
as basal cell carcinoma and squamous cell carcinoma as well as Bowen’s disease 
and keratoacanthomas (Koch et al, 2008). Invasive breast cancer cells express high 
levels of PTPIP51 (Dietel et al, submitted). Comparing prostate carcinoma (PCa) to 
benign prostate hyperplasia (BPH) revealed a specific expression profile in the 
tumour samples. Koch and coworkers (2009b) were able to link this upregulated 
expression to an aberrant promotor methylation status of the PTPIP51 gene in 
prostate cancer in contrast to benign prostate hyperplasia.  
Human neuroepithelial tumours of the human brain display a PTPIP51 expression 
correlated to the malignancy of the tumour. This applies to glioblastoma (GBM) 
WHO °IV in comparison to astrocytoma of lower malignancy WHO grade °II (Petri et 
al 2011) and is now investigated in ependymoma of increasing malignancy 
(Schmidtchen, personal communication). 
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2.1.4 Interacting partners of PTPIP51 
PTPIP51 intervenes in different signalling pathways by its interaction with specific 
proteins standing for signalling knots, which also are basic in tumour progression. 
The interaction behaviour of PTPIP51 is regulated by its tyrosine 176 
phosphorylation status (Brobeil et al 2012a). PTP1B (Protein Tyrosine Phosphatase 
1B) and c-Src are responsible for the correct phosphorylation status of PTPIP51 
(Stenzinger et al, 2009). Thus, PTPIP51 interacts in vitro and in situ with the non-
transmembrane protein-tyrosine phosphatase, dephosphorylating in vitro and in situ 
the Tyr176, and with c-Src which accounts for the phosphorylation [Figure 3]. 
 
 
Figure 3: PTPIP51 and 14-3-3β interacting with Raf-1 when dephosphorylated at 
Tyr 176 by PTP1B, phosphorylation of Tyr 176 by c-Src (Brobeil et al 2012a) 
 
PTP1B contributes to oncogenesis not only by dephosphorylating PTPIP51, but also 
key signalling proteins (Arias-Romero et al, 2009). PTP1B can activate the MAPK 
cascade on Ras and c-Src level probably attributed to PTPIP51. The Src kinase 
activity plays a central role in tumour progression. In prostate carcinoma cell lines 
Src kinase specific activity is directly correlated to metastatic aggressiveness (Xu et 
al, 2012). Specific inhibition of Src kinases impairs malignant glioma growth in vitro 
and in vivo (Stedt et al, 2012). The protein c-Src mediates the phosphorylation of 
EGFR, thereby promoting tumour progression (Tice et al, 1999) and regulates 
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PTPIP51 phosphorylation status balanced by PTP1B activity and in consequence its 
access to the downstream part of EGFR pathway. This reflects the involvement of 
PTPIP51 in tumourigenesis (Stenzinger et al, 2009). 
Recently, two independent studies by Jin et al (2004) and Ewing et al (2007) 
described the interaction with 14-3-3β and 14-3-3γ up to then unknown interaction 
partners of PTPIP51. Meanwhile, further 14-3-3 proteins, namely 14-3-3ζ and 14-3-
3τ, are recognized as interacting partners of PTPIP51 (Bandyopadhyay et al. 2010; 
Ichimura et al. 2013). 14-3-3 proteins, as scaffolding proteins are implicated in 
numerous cellular processes such as tumourigenesis, cell cycle control and 
apoptosis (Cao et al, 2008). An upregulation of 14-3-3 proteins is seen in prostate 
carcinoma (Alaiya et al, 2011). Noteworthy, the expression of 14-3-3β and 14-3-3η 
is correlated to the grade of malignancy in glioma (Yang et al, 2008). In contrast, 
normal brain tissue does not express these two isoforms. In glioblastoma we were 
able to verify the interaction of PTPIP51 with 14-3-3β and corroborated the relation 
of expression level and malignancy in vivo. This was also detected in prostate 
carcinoma where we identified a 14-3-3β colocalization with PTPIP51 protein.  
Yu and coworkers (2008) linked the PTPIP51/14-3-3 interaction with Raf-1. Thereby 
PTPIP51 modulates cellular motility and morphology by this access on the mitogen 
activated protein kinase (MAPK) cascade. This is important in healthy tissue but 
also has a high clinical relevance for the pathogenesis of carcinoma. The 
MAPK/ERK pathway is involved in a variety of cellular functions such as growth, 
proliferation, differentiation, migration and apoptosis. An aberrant regulation of 
MAPK cascades contributes to cancer. In particular, the extracellular signal-
regulated kinase (ERK) of the MAPK pathway has been the subject of intense 
research (Roberts et al, 2007). ERK is a downstream component of an evolutionarily 
conserved signalling module that is activated by the Raf serine/threonine kinases. 
Raf activates the MAPK/ERK kinase (MEK) 1/2 dual-specific protein kinases, which 
then activate ERK 1/2 (Roberts et al, 2007). ERK activation also promotes an 
upregulated expression of EGFR ligands, promoting an autocrine growth loop 
critical for tumour growth. Ras is a downstream effector of the EGFR (Roberts et al, 
2007). The EGFR-Ras-Raf-MEK-ERK signalling pathway has been and is still 
subject of intense analysis to identify new targets for cancer treatment. 
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PTP1B activates the MAPK cascade on Ras level (Stenzinger et al, 2009) and 
regulates the phosphorylation status of PTPIP51, which in turn regulates the 
interaction of PTPIP51 with 14-3-3β. PTPIP51 interacts with Raf-1 through 14-3-3 
thereby modulating the MAPK cascade (Yu et al, 2008). These findings underline 
the important role of PTPIP51 in the EGFR-Ras-Raf-MAPK pathway [Figure 3]. 
 
2.1.5 EGFR – MAPK pathway 
The ultimate cellular response to the activation of EGFR signalling via MAPK 
pathway is DNA synthesis and cell division (Halatsch et al, 2004). Amplification of 
the epidermal growth factor receptor gene (ERBB1) is one of the most common 
oncogenic alterations in GBM (45%), which leads to overexpression of EGFR, thus 
making it a prime target for therapy (Karpel-Massler et al, 2009). 
The epidermal growth factor receptor is a member of the ErbB receptor family, a 
subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-
neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Receptors of the ERBB family 
promote the development of various cancers, and the inhibition of these receptors 
represents an attractive therapeutic concept. Inhibition of the ERBB1 receptor can 
inhibit migration of human glioblastoma cells (Staberg et al, 2013). 
In about 40-50% of cases of glioblastoma multiforme (GBM) the epidermal growth 
factor receptor (EGFR) is overexpressed (Ewing et al, 2007; Hegi et al 2012), and 
almost half of these cases co-express the mutant receptor subtype EGFRvIII. This 
EGFR variant is constitutively activated, and thereby may contribute to the 
aggressive and refractory course of GBM, which is associated with a median 
survival of only 40 to 60 weeks from diagnosis (Loew et al, 2009). However, efforts 
at targeting the EGFR tyrosine kinase using small molecule inhibitors or antibodies 
so far have shown disappointing efficacy in clinical trials for newly diagnosed or 
recurrent glioblastoma (Hegi et al, 2012).  
Based on these findings we investigated the expression profile of PTPIP51 and its 
interaction partner 14-3-3β in brain tumours (low grade astrocytomas and 
glioblastomas). In a second step we transferred the new informations on 
glioblastoma cells to get more insights into the effects of EGFR inhibition on 
PTPIP51and 14-3-3β. The results suggest a correlation between MAPK pathway 
Introduction 
 
 9 
inhibition via ERGR and downregulation of PTPIP51 and 14-3-3β expression. 
Interestingly, this hypothesis argues for a reverse feedback on transcriptional and 
translational level of both proteins in case of depressed stimulation of EGFR-Ras-
Raf-MAPK pathway.  
 
Figure 4: EGFR – MAPK signalling pathway with PTPIP51, 14-3-3β and PTP1B 
 
The tissue specific expression profiles of PTPIP51 and its interactions with 
important signalling proteins being essential for pathways promoting cancer 
development and progression argue for an important functional role of PTPIP51 in 
cancer pathogenesis.  
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2.2 Prostate carcinoma 
2.2.1 Background 
Prostate cancer (PCa) is the most common non-skin cancer and the second leading 
cause of cancer-related death for men in the United States (Farrell et al, 2013; 
Smith et al, 2009). Compared to other carcinomas, it has a relative low mortality but 
a high incidence (Farrell et al, 2013). Despite a large increase in prostate cancer 
incidence, mortality rates have remained relatively constant through improvements 
in survival. Most patients present with a localized disease, but there are still many 
who present with an already metastasized stage (Chowdhury et al, 2013). From 
1982 to 2006, new cases increased from 80 to 309 per year in Luxembourg, while 
the incidence (world standard population) rose from 29.5 to 85 per 100 000 men 
(Lamy et al, 2013). One of 34 patients with diagnosis of prostate carcinoma dies 
because of the cancer (Crawford, 2003). 
Since 1960 the Gleason grading system has become the most commonly used 
grading system for prostate cancer in the United States and is gaining worldwide 
acceptance (Guimaraes et al, 2008). Increasing age, ethnic origin, and family history 
are well-established risk factors for the diagnosis of prostate cancer (Glass et al, 
2013). Aside from that increased insulin growth factor (IGF) concentration was 
detected as a risk factor (Grönberg, 2003; Tsuchiya, 2013). 
Most cancers have the potential to metastasize under appropriate conditions, PCa 
favours the skeleton as the primary site of metastasis, suggesting that the bone 
microenvironment is conducive to its growth (Hudson et al, 2013).  
PCa metastases proceed through a complex series of molecular events that induce 
angiogenesis at the site of the primary tumour, local migration within the primary 
site, intravasation into the blood stream, survival within the blood circulation, 
extravasation of the tumour cells to the target organ and colonization of tumour cells 
within the new site. One of the mechanisms leading to PCa metastases is the 
perineural invasion of tumour cells (Martinez et al, 2013). Each one of these steps 
involves a complicated chain of events that utilize multiple protein – protein 
interactions, protein signaling cascades and transcriptional changes (Hudson et al, 
2013). 
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Despite PCa is subject to intense research and the urgent need to improve current 
biomarkers for diagnosis, prognosis and drug resistance, the advances have been 
very slow. Standard therapy so far includes surgical resection, radiochemotherapy 
and androgen deprivation therapy (Chowdhury et al, 2013). 
 
2.2.2 Interacting partners of PTPIP51 in prostate carcinoma 
The deregulation of the epidermal growth factor receptor (EGFR) pathway plays a 
major role in the pathogenesis of prostate cancer. However, therapies targeting 
EGFR have demonstrated limited effectiveness in PCa (Carrion-Salip et al, 2012). A 
potential mechanism to overcome EGFR blockade in PCa cells is the autocrine 
activation of alternative receptors of the human EGFR (HER) family through the 
overexpression of the HER receptors and ligands (Carrion-Salip et al, 2012). This 
mechanism seems to play a key role in mediating resistance to EGFR inhibition in 
PCa cells, but is still poorly understood.  
C-Src integrates a large number of signal transduction pathways regulating cell 
division, migration and other aspects of cell physiology. As already mentioned 
before, c-Src regulates the EGFR/MAPK pathway [Figure 4]. Mutations of Src 
kinase have not been described in human PCa, but there is evidence for an 
increased level of expression accompanying cancer progression (Cai et al, 2011). In 
case of enhanced c-Src expression coupled to the raised expression of androgen 
receptors, it results in a strong activation of Src kinase activity accompanied by 
activation of the MAPK pathway and increased activity of the androgen receptors 
(Cai et al, 2011). 
As shown in figure 3, Ras is part of the EGFR/MAPK pathway. To identify additional 
pathway alterations that cooperate with PTEN (phosphatase and tensin homolog) 
tumour suppressor gene loss in prostate cancer progression, Mulholland and 
coworkers (2012) surveyed human prostate cancer tissue microarrays and found 
that the RAS/MAPK pathway is significantly elevated in both primary and metastatic 
lesions. Although Ras activation alone cannot initiate prostate cancer development, 
it significantly accelerates progression caused by PTEN loss, accompanied by 
epithelial-to-mesenchymal transition (EMT) and macrometastasis with 100% 
penetrance (Mulholland et al, 2012). 
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Ren and coworkers postulated the activation of the Ras/Raf/MEK/ERK pathway to 
be frequent in prostate cancer of Chinese men, with Raf gene copy number gain 
potentially being the main contributor of this (Ren et al, 2012).  
PTP1B stimulates EGFR/MAPK pathway on c-Src and Ras level as described 
above. PTP1B is induced through the stimulation of androgen receptors in androgen 
receptor expressing prostate cancer cells at the mRNA and protein level, which 
increases PTP1B activity (Lessard et al, 2012).  
 
2.2.3 PTPIP51 in prostate carcinoma 
 
Figure 5: Graphical abstract of the most important results of the first publication 
submitted for thesis: PTPIP51 mRNA and protein expression in tissue microarrays 
and promoter methylation of benign prostate hyperplasia and prostate carcinoma 
(Koch P, Petri MK et al, 2009) 
 
PCa – Prostate carcinoma 
BPH – benigne prostate hyperplasia 
Protein expression profile 
Promotor methylation mRNA - in situ hybrization 
PCa BPH 
mRNA – RT PCR 
Hypomethylation in PCa 
compared to BPH  
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PTPIP51 mRNA and protein expression levels in prostate carcinoma (PCa) 
compared to benign prostate hyperplasia (BPH) were investigated either by PCR or 
by immunocytochemistry in tissue microarrays.  
This study demonstrated a cell specific expression of PTPIP51 mRNA and protein in 
BPH and PCa. Quantitative real-time PCR analysis showed slightly elevated levels 
of PTPIP51 mRNA in the group of PCa specimen when compared to BPH 
specimen. These findings corroborated the results of in situ hybridization 
experiments. PTPIP51 protein was investigated by immunohistochemistry. 
Comparing the protein expression of both investigated groups, a higher expression 
of PTPIP51 was detected in PCa samples compared to BPH samples. All PCa 
samples exhibited an increased quantity of ganglia and nerve fibres. All these 
ganglia and nerve fibres were highly positive for the PTPIP51 protein. In prostate 
cancer nerve, the nerve fibres play an important role, amongst others being 
responsible for tumour spreading and supporting tumour growth. As mentioned 
above, perineural invasion is general mechanism in prostate cancer (Martinez et al, 
2013). All ganglia and nerve fibers of the prostate cancer samples as well as of BPH 
presented with a strong expression of PTPIP51 protein. The observed higher levels 
of PTPIP51 mRNA and protein in PCa compared to BPH can probably be explained 
by the higher nerve density reported for PCa as a consequence of cancer-related 
axogenesis and neurogenesis (Ayala et al, 2008). 
PTP1B was partially co-expressed with PTPIP51 in prostatic epithelial cells (BPH) 
and in prostate tumour cells (PCa). In endothelial cells the co-expression of both 
antigens was restricted to the PCa samples. This finding may implicate a functional 
role of PTP1B dephosphorylated PTPIP51. Dephosphorylation allows PTPIP51 to 
interact with 14-3-3/Raf1 thus activating MAPK signaling (Brobeil et al 2012a) 
[Figure 3]. This promotes angiogenesis, which is an important prerequisite of 
pathogenesis in cancer. A stringent cell specific co-expression of PTPIP51 with c-
Src was not detected. On subcellular level we found Raf-1 co-expressed with 
PTPIP51 in the basal part of prostatic epithelial cells (BPH) and in a part of the 
tumour cells (PCa). Endothelial cells and a subset of immune cells as well displayed 
a co-expression of both antigens in BPH and in PCa. These findings correlated to 
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co-expression of PTPIP51 with 14-3-3β, being the precondition for the interference 
of PTPIP51 in the MAPK pathway.  
 
2.2.4 Promotor methylation in PCa and BPH 
The regulation of transcription was examined by investigating the promotor 
methylation status of PTPIP51 in both BPH and PCa. In general, methylation of the 
promotor region is associated with gene silencing (Li et al, 2003). In contrast, a lack 
of methylation is responsible for decondensation of chromatin genomic instability 
and may cause activation of retrotransposon elements, which results in an aberrant 
overexpression of certain genes (Jones et al, 1999; Tuck-Muller et al, 2000). 
Therefore, we investigated PTPIP51 promotor methylation [Figure 6] in samples of 
BPH and PCa.  
  
Figure 6: PTPIP51 promotor methylation 
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Figure 7: Methylation of PTPIP51 promotor gene in PCa and BPH. Black circles 
correspond to methylated CpGs, open circles correspond to unmethylated CpGs. 
Bar diagram demonstrates aggregated representation of methylation data of every 
CpG nucleotide within the DNA fragment of the PCa and BPH group. 
 
Eighteen CpGs (Cytosin-phosphatidyl-Guanin) were characterized from each 
sample by sodium bisulfite sequencing. In contrast to 78% methylated CpGs in 
BPH, there was a loss of methylation observed in PCa [Figure 7]. Overexpression of 
PTPIP51 as a result of CpG island hypomethylation might be a potential factor 
contributing the perineural invasion in PCa. 
This study presented differences in PTPIP51 gene methylation in PCa compared to 
BPH and a tissue-, cell- and pathology specific expression of PTPIP51 protein.  
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2.3. Glioblastoma 
2.3.1 Background 
The Glioblastoma (GBM) is the most common and most malignant primary brain 
tumour. They account for 10-15 % of all intracranial tumours and 50-60 % of the 
astrocytic gliomas. Every year there are 12 000 glioblastomas diagnosed in the US. 
The prognosis of GBM is still poor with a median survival of 12 months (Marko et al, 
2013). The annual incidence is approximately two to three new cases per 100 000 
population. Adult patients are affected most commonly with a peak incidence 
between 50-70 years of age, but GBMs develop at any age (Reifenberger et al, 
2010). GBM is still one of the most lethal cancers in humans. The so called long-
term survivors are patients, who are alive after three years from diagnosis. 
According to the World Health Organization (WHO) classification of tumours of the 
central nervous system, including the latest version 2007, GBM belongs to the 
subgroup of atrocytic tumours which are members of the tumours of neuroepithelial 
tissue and is grade WHO IV (Louis et al, 2007).  
 
Tumor 
group 
Tumor entity Grade I Grade II Grade 
III 
Grade 
IV 
Astro-
cytic 
tumors 
Pilocytic astrocytoma x    
Pilomyxoid astrocytoma  x   
Subependymal giant cell 
astrocytoma 
x    
Pleomorphic xanthoastrocytoma  x   
Diffuse astrocytoma  x   
Anaplastic astrocytoma   x  
Glioblastoma    x 
Gliomatosis cerebri  (x) x (x) 
Table 1: WHO grading of tumours of the central nervous system (here only the 
astrocytic tumor classification shown) (Louis et al, 2007) 
 
The diagnosis of GBM is based on specific histopathological features. Glioblastoma 
are cellular, highly anaplastic tumours that may be composed of cells with various 
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morphologies, including fibrillar and gemistocytic cells, fusiform cells, small 
anaplastic cells and multinuclear giant cells. Atypical nuclei are usually marked, and 
mitotic activity, including atypical forms, is prominent. The presence of 
microvascular proliferation and / or necrosis is essential for the diagnosis. 
Microvascular proliferation often results in GBM–typical so called glomerulum- or 
garland-like capillary structures (Reifenberger et al, 2010). In glioblastoma primary 
and secondary GBMs are distinguished. Primary GBMs are newly diagnosed 
tumours and secondary GBMs develop from astrocytomas of lower malignancy. 
There are specific molecular aberrations frequently detected in different types of 
diffusely infiltrating astrocytic gliomas (Reifenberger et al, 2004). 
Nuclear p53 immunoreactivity can be detected in 30-40% of all GBMs, with giant 
cell GBM and secondary GBM being p53 positive in up to 80 % of the cases. Strong 
expression of the EGFR is found in about 60 % of primary glioblastoma, but is rare 
in secondary glioblastoma. The MIB 1 (antibody against Ki 67) labelling index is 
usually high (> 10 %), but often shows marked regional heterogeneity (Reifenberger 
et al, 2010). 
The current standard therapy for GBM is multimodal according to the Stupp 
protocol, consisting of surgery with targeted macroscopic total resection, 
radiotherapy with concomitant temozolomide alkylating chemotherapy and six 
adjuvant temozolomide therapy cycles (Shah et al, 2011). Usually the tumours recur 
after this therapy. Surgical resection is often limited by involvement of eloquent brain 
areas. But even in case of macroscopic total resection of the tumours without any 
gadolinium enhancement in postoperative MRI and the following radiochemotherapy 
the GBM recidivates in nearly every case. 
 
2.3.2 Interacting partners of PTPIP51 in glioblastoma 
Amplification of the epidermal growth factor receptor gene (ERBB1) is one of the 
most common oncogenic alterations in GBM (45%), which leads to overexpression 
of EGFR, thus making it a prime target for therapy (Karpel-Massler et al, 2009; Hegi 
et al, 2012). In clinical trials beside standard therapy the therapy with EGFR 
targeting agents alone in clinical trials has not generated promising results to date 
(Gao et al, 2013). Strategies are now focusing on blocking the downstream EGFR-
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activated metabolic pathways and their key phosphorylated kinase alterations in 
GBMs (Gao et al, 2013). Almost half of GBM cases with overexpressed EGFR do 
co-express the mutant receptor subtype EGFRvIII. This EGFR variant is 
constitutively activated, and thereby may contribute to the aggressive and refractory 
course of GBM, which is associated with a median survival of only 40 to 60 weeks 
from diagnosis (Loew et al, 2009). 
In GBM, Ras activity is upregulated in the majority of the tumours. Furthermore, the 
levels of MAPK/ERK, a known downstream effector of Ras, are also increased 
(Lyustikman et al, 2008). Downregulation of RAS can inhibit glioblastoma cell 
growth through preventing RAS signaling (Cao et al, 2012).  
Lyustikman and coworkers (2008) detected increased levels of Raf-1 and BRAF 
proteins and Raf kinase activity in human GBM samples. The oncogenic effect of 
KRas in glioma formation is transduced at least in part through Raf signaling 
(Lyustikman et al, 2008). 
PTP1B contributes to oncogenesis by tyrosine dephosphorylation of key signaling 
proteins (Arias-Romero et al, 2009) and additionally activates c-Src (Bjorge et al., 
2000) and stimulates the MAPK cascade on Ras level. So far its role in GBM 
pathology only is marginally investigated so far. The vascular endothelial growth 
factor (VEGF) directly regulates tumour cell invasion negatively through enhanced 
recruitment of PTP1B (Lu et al, 2012). 
In gliomas there is a correlation between the grade of malignancy and the 
expression levels of 14-3-3β and 14-3-3η (Yang et al, 2008). In contrast, normal 
brain tissue does not express these both isoforms. The isoforms β and η belong to a 
superfamily of 14-3-3 proteins, which are differently expressed in many human 
tissues. 14-3-3 proteins have been implicated in numerous cellular processes, such 
as tumourigenesis, cell cycle control and apoptosis (Cao et al, 2008).  
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2.3.3 PTPIP51 in glioblastoma 
 
Figure 8: Graphical abstract of the most important results of the second publication 
submitted for thesis: PTPIP51, a positive modulator of the MAPK/Erk pathway, is 
upregulated in glioblastoma and interacts with 14-3-3β and PTP1B in situ. (Petri et 
al 2011) 
 
PTPIP51 expression was investigated in glioblastoma on transcriptional and 
translational level by immunohistochemestry, in situ hybridization and RT PCR. 
Quantitative data of PTPIP51 expression in GBM was compared to the level in 
WHO grade II astrocytoma by quantitative RT PCR. An in situ interaction of 
PTPIP51 with its expected interacting partners 14-3-3β and PTP1B was verified by 
Duolink proximity ligation assays [Figure 9: DPLA]. 
GBM IV 
Astro II 
GBM WHO grade IV Astro WHO grade II 
Protein interaction profile(Duolink Proximity ligation assay) 
mRNA (quantitative RT PCR) 
Protein expression profile 
mRNA (in situ hybridization) 
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Figure 9: Technique description of Duolink proximity ligation assay (DPLA). 
 
This study revealed a cell specific expression of PTPIP51 mRNA and protein in 
human glioblastoma. Immunehistochemical experiments and in situ hybridization 
displayed a strong expression of mRNA and PTPIP51 protein in GBM tumour cells, 
endothelial cells, immune cells within the lumina of tumour vessels as well as in the 
tumour infiltrating immune cells. In endothelial cells of normal and of 
pseudoglomerular vessels PTPIP51 protein was restricted to the plasmamembrane 
and to the nucleus indicating the expression of specific membrane associated 
PTPIP51 isoforms in these cells. Granulocytes located in capillary lumina or 
infiltrating the tumour as well as in the necrotic areas displayed a strong cytoplasmic 
PTPIP51 expression. This is in contrast to B-lymphocytes, which did not show any 
PTPIP51 expression. 
PTPIP51 and 14-3-3β showed a strict co-localization. Both proteins were seen in 
glioblastoma cells, endothelial cells and granulocytes. The glioblastoma cells 
displayed a strong cytoplasmic reaction for both proteins. Grade II astrocytoma also 
displayed a co-localization of PTPIP51 and 14-3-3β, but to a much lower extent 
[Figure 8]. 
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This was confirmed by a decreased mRNA level of PTPIP51 in WHO grade II 
astrocytoma compared to glioblastoma [Figure 8]. Comparable observations of a 
correlation to the grade of malignancy in glioma have already been described for 14-
3-3β alone (Yang et al, 2008).  
As mentioned above, 14-3-3β mediates the interaction of PTPIP51 with Raf-1, 
thereby modulating the activity of the MAPK signaling pathway (Lv et al, 2006, Yu et 
al, 2008; Stenzinger et al, 2009). The MAPK pathway plays an important role in cell 
migration and thereby seems to be one of the main reasons for recurrence and poor 
prognosis of GBM. It is considered that migrating tumour cells infiltrate the healthy 
tissue surrounding the glioblastoma and thereby can escape surgical extirpation as 
well as radiotherapy and by this way give rise to regrowth.  
To sum up, PTPIP51 plays an important role in glioblastoma on the level of 
EGFR/MAPK pathway by its interaction with 14-3-3β. 
 
 
2.4 PTPIP51 and EGFR/MAPK pathway – regulatory role in tumour 
progression 
2.4.1 Background 
Recently, we detected a tissue specific expression of PTPIP51 in prostate 
carcinoma. Here we could verify an increased level of PTPIP51 mRNA and protein 
in carcinoma compared to benign prostate hyperplasia and a hypomethylation of 
PTPIP51 promotor in cases of PCa. Moreover, PTPIP51 was co-localized with 14-3-
3β. 
Samples of glioblastoma displayed a tissue specific expression of PTPIP51. In 
relation to the values seen in low-grade astrocytoma we could verify a higher level 
of mRNA and protein of PTPIP51 in GBM (WHO grade IV). Beside these identical 
features for both tumour entities (GBM and PCa), we were able not only to disclose 
a co-localization of PTPIP51 and 14-3-3β, but also the interaction of both proteins in 
vivo verified by the Duolink proximity ligation assay. 
Taken together, PTPIP51 is highly expressed in carcinomas and thus modifies the 
EGFR/MAPK pathway of carcinomas as is emphasized by its interaction with 14-3-
3β. On cellular level the interaction of PTPIP51 with 14-3-3β leads to a ternary 
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complex with cRAF (Raf1) stimulating the downstream effector EGFR/MAPK 
signaling-pathway (Yu et al, 2008). Interestingly, a positive correlation between the 
grade of tumour malignancy in gliomas with the PTPIP51 interacting partner 14-3-3β 
has been described before (Yang et al, 2008).  
These findings suggest that both proteins may play a functional role in the 
tumorigenesis of glioblastomas in particular.  
 
 
 
 
 
Figure 10: The tyrosine kinase inhibitor Gefitinib and the monoclonal antibody 
Cetuximab treatment of EGFR – MAPK signalling pathway  
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2.4.2 PTPIP51 in GBM cells during inhibition of EGFR 
 
Figure 11: Graphical abstract of the most important results of the third publication 
submitted for thesis: PTPIP51 levels in glioblastoma cells depend on inhibition of the 
EGF-receptor (Petri et al, 2015) 
 
Hence, we investigated the interfering effect of the tyrosine kinase inhibitor Gefitinib 
and the monoclonal antibody Cetuximab on growth factor signaling in vitro and in 
vivo. In vitro investigations were performed with the U87 cell line as an established 
model system. To record the in vivo effects, primary cells from GBM patients were 
cultured and treated with either Gefitinib or Cetuximab. Treatment efficiency was 
controlled by the quantification of cell viability measured by the metabolic rate and 
by cell counting. PTPIP51 and 14-3-3β expression was evaluated in untreated 
(control) and treated cells by double immunostainings and its mRNA levels by 
quantitative real time PCR [Figure 11]. 
U87 cell line 
Gefitinib Cetuximab Control 
3 different concentrations of inhibitor 
36h 
48h 
72h 
96h 
Culture slides 
Number of cells 
Cell metabolism  
(Alamar blue test) 
PTPIP51 & 14-3-3β mRNA 
no significant change 
(quantitative RT PCR) 
Protein expression (double immunehistochemestry) Changed interaction  
profile (DPLA) 
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Taken together, Gefitinib treatment of GBM cells resulted in a reduced cell 
proliferation and cellular metabolic rate. These effects were directly correlated to the 
time of exposure and to the applied concentration of the tyrosine kinase inhibitor. 
Interestingly, compared to the untreated reference cells the inhibition by Gefitinib 
resulted in lower PTPIP51 and 14-3-3β protein expression level correlated to the 
applied inhibitor concentration. The mRNA level did not show significant change but 
the PTPIP51 interaction profile changed in correlation to the applied Gefitinib 
[Figure 11, 12]. 
. 
 
Figure 12: Changes in the interaction profile of PTPIP51 by Gefitinib treatment in a 
time and dose dependent manner 
 
The use of the monoclonal antibody Cetuximab did not affect the number of viable 
cells. Their metabolic rate was marginally depressed in relation to the applied 
Cetuximab concentration. The mRNA and protein expression levels of PTPIP51 as 
well as of 14-3-3β remained unaffected by Cetuximab treatment. 
These findings confirm a direct relation between PTPIP51 and 14-3-3β with the 
EGFR/MAPK signalling pathway in glioblastoma. 
Cetuximab did neither influence PTPIP51 mRNA expression nor tumour cell 
proliferation rate. As a monoclonal antibody, Cetuximab binds to the extracellular 
part of the EGFR, thus abolishing the binding of ligands such as EGF. A slight 
reduction of cellular metabolism was the only dose dependent effect of Cetuximab 
treatment. This neletible effect of the monoclonal antibody may be explained by the 
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intrinsic and independent phosphoactivation of mutant EGFR dimer configuration 
which shows a high prevalence in GBM (Gajadhar et al, 2012). 
As a tyrosine kinase inhibitor (TKI) Gefitinib influences this intrinsic EGFR activation 
of the MAPK pathway. But, despite the distinct effect of Gefitinib treatment in GBM 
cell culture experiments the clinical context did not reach this effect. Clinical trials 
using EGFR inhibitors demonstrated only modest improvements in a small 
percentage of GBM patients, suggesting that many GBMs possess intrinsic 
resistance or rapidly acquire resistance to EGFR inhibition (Clark et al, 2012). 
Our study identified PTPIP51 as a scaffolding protein influencing the EGFR/MAPK 
pathway in glioblastoma. In consequence, analysis of PTPIP51 expression could 
indicate the therapeutic response to anti-EGFR therapy by Gefitinib. Further studies 
are needed to understand the potential of interference in the EGFR phosphorylation 
independent regulatory circuits, in order to make the MAPkinase pathway sensitive 
for the knock down of PTPIP51. 
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2.5 Ongoing Questions 
Taking into account the involvement of PTPIP51 in the important MAPK signaling 
pathway in different tumours, knock down experiments by siRNA are needed to get 
more insights into the role of PTPIP51 in tumour progression. 
The present studies revealed a tissue specific higher expression of PTP1B in 
glioblastoma. Its stimulating effects on the EGFR/MAPK pathway has previously 
been described in various malignancies but not in glioma so far. Further studies are 
needed to explore its importance and relation to PTPIP51 function in this type of 
tumour to disclose possible intervention mechanisms. 
The similarities of PTPIP51 features and that of its interacting partners in prostate 
carcinoma and glioblastoma suggest a central role of PTPIP51 in the EGFR/MAPK 
signalling in prostate carcinoma. This hints to a probable common mechanism for 
affecting both tumour entities on the level of PTPIP51. Thus, the consecutive 
studies have to be expanded on cultured prostate cancer cells. 
PTPIP51 promotor methylation studies are of great importance in pathogenesis and 
progression of glioma. An investigation of the methylation status in the long-term-
survivors of glioblastoma patients would be of enormous interest. This data could 
become a prognostic predictor for therapy by EGFR inhibitors or PTPIP51 
modulating molecules, corresponding to the clinical established MGMT promotor 
methylation status being a prognostic predictor of therapy with temozolomide. 
As a tumour specific expression profile of PTPIP51 was detected in our laboratory, 
ongoing investigations of PTPIP51 as a molecular marker for ependymoma 
classification are in progress. 
A further analysis of PTPIP51 expression in neuroepithelial tumour entities, being  
not included in the presented studies aside from diffuse astrocytoma WHO grade II, 
glioblastoma and several ependymomas, is necessary. These studies probably 
could help to sub-classify the tumours according to their PTPIP51 expression. What 
about PTPIP51 expression in oligodendroglial glioma and pilocytic glioma? What is 
the basis for the high PTPIP51 protein concentration in endothelial cells of 
neuroepithelial tumours of the choroid plexus tumours? 
With the background of high PTPIP51 expression in the nerve fibres of prostate 
cancer its expression profile in neuroma and schwannoma could be very insightful. 
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In prostate carcinoma and glioblastoma a strong expression of PTPIP51 was 
detected in granulocytes in the capillaries of the tumour tissue as well as in the 
tumour infiltrating granulocytes. PTPIP51 probably plays an important role in the 
regulation of the immune system. Up to now, this has not been investigated. 
The evolutionary conserved protein PTPIP51 has been detected in various different 
organs, tissues and cell types. This could implicate a basal function in every cell, as 
for example every cell uses MAP kinase signalling. But, there are some types of 
cells, which are lacking PTPIP51 e.g. B-lymphocytes. Further studies are needed to 
explore a correlation of PTPIP51 expression in relation to the cell type. 
Latest research findings reported the influence of PTPIP51 on calcium homeostasis 
in neuronal cells by its interaction with VAPB, thus linking the endoplasmatic 
reticulum to mitochondria (Stoica et al, 2014). Pertubated calcium signaling can 
affect tumour growth. Investigation of VAPB interaction will give better insights into 
tumour growth regulation. Gürsel and coworkers (2015) suggested to target GSK3β 
in glioblastoma stem-like cells combined with current therapeutic options. Current 
studies in our laboratory revealed the interaction of PTPIP51 and GSK3β stressing 
its function as scaffolding protein. Yet, further studies are required to disclose the 
function of PTPIP51 in GSK3β signaling. 
Basing on the growing knowledge of various tumour entities and their characteristic 
details, e.g. mutation and receptor status and in consequence deteriorated 
intracellular signalling, there is an increasing demand for personalized therapies. Up 
to now, there exist several possibilities for such a personalized therapy basing either 
on specific antibodies, on tyrosine kinase inhibitors or small molecular inhibitors. 
Most of these therapies intervene very early in the signalling pathways on the 
upstream region of the se pathways resulting in the development of resistances of 
the tumour cells to the treatment. 
PTPIP51 is a protein being part of numerous signalling knots in many deteriorated 
tumour relevant signalling pathways. Certainly, there will be crosstalks between 
some of these tumour relevant pathways. Therefore one of the upcoming questions 
will be the disclosure of such crosstalks on PTPIP51 level. 
Recently, PTPIP51 became drugable by the development of the specific small 
molecule modulator LDC3 (Brobeil et al, Hoenig et al, submitted). LDC3 affects the 
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interaction profile of PTPIP51, thus changing the downstream activation of these 
pathways (Brobeil et al, submitted). 
Yet, the presented studies give an important insight in the characteristics of 
PTPIP51 in glioma and prostate cancer giving the basis for therapeutic options. 
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3. Summary 
3.1 Summary  
To sum up, PTPIP51 is overexpressed in prostate carcinoma compared to benign 
prostate hyperplasia and in glioblastoma WHO grade IV compared to WHO grade II 
astrocytoma. In both tumour entities PTPIP51 shows a tissue specific expression 
profile. 
For the first time we could link the methylation status of PTPIP51 in prostate 
carcinoma and benign prostate hyperplasia to the observed altered expression 
profiles. Here we found a hypomethylation in prostate cancer, which was not seen in 
benign prostate hyperplasia. This probably explains the higher expression of 
PTPIP51 in PCa in comparison to BPH on protein level which is reflected on the 
mRNA level. 
The interaction of PTPIP51 with 14-3-3β was identified to lead to a ternary complex 
with cRAF (Raf1) stimulating the downstream effector of the EGFR/MAPK signaling-
pathway. This pathway plays an essential role in cell proliferation and migration, 
which is especially crucial for the progression of carcinoma. The co-localization of 
PTPIP51 with 14-3-3β, Raf-1 and PTP1B was as well identified in prostate 
carcinoma as in glioblastoma. These findings underline the important role of 
PTPIP51 in the EGFR/MAPK pathway in cancer.  
PTP1B is expressed in the investigated tumour samples displaying a similar cellular 
distribution comparable to that of PTPIP51. As PTP1B regulates the 
phosphorylation status of PTPIP51, which in turn regulates the interaction of 
PTPIP51 with 14-3-3β, we postulate a changed interaction profile of PTPIP51 in 
tumours. 
Glioblastoma overexpress EGFR as well as the mutant form EGFRvIII. Therefore, 
the regulatory potential of PTPIP51 on the downstream part of the EGFR/MAPK 
pathway was investigated in glioblastoma cells. Interestingly, we were able to 
demonstrate a direct correlation between the successful inhibition of EGFR by the 
tyrosine kinase inhibitor Gefitinib treatment led to downregulated expression of 
PTPIP51 and 14-3-3β on protein level and a changed interaction profile, 
emphasizing the important influence of PTPIP51 on EGFR signaling in tumours. 
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In summary, these investigations present an important basis for numerous following 
studies of PTPIP51 regulation in tumours. Of particular interest is the functional 
implication of PTPIP51 in neuroepithelial tumours and its clinical relevance as 
molecular marker in staging or as a target in new therapy strategies. 
  
3.2 Zusammenfassung 
Zusammenfassend läßt sich festhalten, dass PTPIP51 sowohl in Prostata 
Karzinomen verglichen mit benigner Prostata Hyperplasie, als auch in 
Glioblastomen WHO °IV verglichen mit WHO Grad II Astrozytomen eine erhöhte 
Expression aufweist. In beiden Tumorentitäten weißt PTPIP51 eine 
gewebespezische Expressionsverteilung auf, die in den vorgelegten Publikationen 
zum ersten Mal beschrieben wurde. 
In Prostata Karzinomen konnten wir erstmalig einen hypomethylierten Status der 
Promotorregion des PTPIP51 Gens nachweisen, welche in der benignen Prostata 
Hyperplasie nicht nachweisbar war. Dies ist eine mögliche Basis für die 
Überexpression von PTPIP51 in Prostata Karzinomen. 
Über die Interaktion mit 14-3-3β bildet PTPIP51 einen Komplex mit Raf-1, was über  
Raf-1 vermittelt den EGFR/MAPK Signalweg stimuliert. Dieser Signalweg spielt eine 
wichtige Rolle bei der Proliferation und Migration. Dies sind Prozesse, die essentiell 
für die Progression von Karzinomen sind. Die Co-Lokalisationen von PTPIP51 
mit14-3-3β, Raf-1 und PTP1B konnten sowohl im Prostata Karzinom als auch im 
Glioblastom nachgewiesen werden. Dies weist auf eine zentrale Rolle des  PTPIP51 
im EGFR/MAPK Signalweg der Karzinome hin.   
PTP1B weist ein ähnliches Verteilungsmuster wie PTPIP51 in den untersuchten 
Karzinomen auf. Über die Interaktion der PTP1B mit PTPIP51 wird PTPIP51 
dephosphoryliert, was wiederum die Interaktion des PTPIP51 mit Raf1 reguliert und 
somit zu einer erhöhten Aktivierung des MAPK Signalweges in den Karzinomen 
führt.  
Da eine Überexpression von EGFR sowie die Expression einer dauerstimulierten 
mutierten Form des EGF-Rezeptors, EGFRvIII, besonders in der Pathogenese von 
Glioblastomen eine Rolle spielt, war ein zentraler Punkt der Untersuchungen die 
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Frage nach der Regulation von PTPIP51 und dem EGFR/MAPK Signalweg in 
Glioblastomzellen. Es ließ sich ein direkter Zusammenhang zwischen der 
erfolgreichen Hemmung des EGFR durch den Tyrosin Kinase Inhibitor Gefitinib und 
der Expression von PTPIP51 auf Proteinebene, sowie ein verändertes 
Interaktionsprofil nachweisen. 
Diese Arbeiten bilden die Basis für weitere interessante Studien zu PTPIP51. Von 
besonderem Interesse ist die Beteiligung von PTPIP51 an neuroepithelialen 
Tumoren und dessen Rolle als molekularer Marker oder Angriffspunkt für klinisch 
relevante Interventionen, die letztendlich zu einem möglichen Therapieansatz 
führen könnten.  
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BACKGROUND. Protein tyrosine phosphatase interacting protein 51 (PTPIP51) shows a
tissue-speciﬁc expressionpattern and is associatedwith cellular differentiation andapoptosis in
several mammalian tissues. Overexpression of the full-length protein enhances apoptosis. It is
also expressed in various carcinomas. In this study the expression of PTPIP51 and its in vitro
interaction partners was investigated in human benign prostate hyperplasia (BPH) and in
prostate carcinoma (PCa).
METHODS. Tissue microarrays of human BPH and PCa were analyzed by immunohisto-
chemistry. For polymerase chain reaction (PCR), cryo samples of BPH and PCa were used.
Bisulﬁte DNA treatment, followed by sequencing of PCR products was performed in order to
analyze CpGs methylation within the promoter region of the PTPIP51 gene.
RESULTS. PTPIP51 mRNA and protein expression was detected in prostatic epithelia of BPH
and in tumor cells of PCa, respectively, and within smooth muscle cells of the stromal
compartment.A stronger expressionwaspresent innerveﬁbers, particularly in PCa, in immune
cells and in smoothmuscle and endothelial cells of vessels of BPH and PCa. OnmRNA levels, a
slightly elevated expression of PTPIP51 was observed in the PCa group as tested by real-time
quantitative PCR analyses. Methylation experiments revealed that at least 70% of methylated
CpGs in theCpG islandof thePTPIP51 genepromoter regionwere identiﬁed inBPHsamples. In
contrast, a loss of methylation has been found in the PCa group.
CONCLUSION. The promoter methylation status of PTPIP51 seems to inﬂuence the
expression of PTPIP51, which was seen as elevated in the PCa. Prostate 69: 1751–1762,
2009. # 2009 Wiley-Liss, Inc.
KEY WORDS: PTPIP51; benign prostate hyperplasia; prostate carcinoma; perineural
invasion; promoter methylation status; PTP1B
INTRODUCTION
Protein tyrosine phosphatase interacting protein 51
(PTPIP51, SwissProt accession code Q96SD6) is an
evolutionary conserved protein, consisting of 470 amino
acids. It was originally detected by a yeast-two-hybrid
screen as an interaction partner of two non-transmem-
brane protein-tyrosine phosphatases, PTP1B and TcPTP
[1]. The interaction takes place in the region between
amino acids 78 and 214. In vitro and in HEK293 cell, the
protein is phosphorylated at Tyr176 by Src kinase.
Dephosphorylation is exerted by PTP1B and TcPTP [2].
In mammals, PTPIP51 is expressed in highly dif-
ferentiated tissue, particularly in follicular and inter-
follicular epidermis, epithelia, skeletal muscle, testis,
andnervous tissue [3]. PTPIP51protein alsoplays a role
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during mammalian development [4] and both, mRNA
and protein could be traced during placental villi
formation [5] and in various carcinomas [6,7].
The regulation of the PTPIP51 expression was inves-
tigated in immortalized human keratinocytes (HaCaT
cells). Epidermal growth factor (EGF), known to
promote proliferation, resulted in a reduced PTPIP51
expression, whereas differentiation, promoted by
1,25(OH2)D3, resulted in an enhanced PTPIP51 expres-
sion, detected by immunohistochemistry [8].
As demonstrated by Lv et al. [7], PTPIP51 over-
expression induces apoptosis in HEK293 cells.
Recent pull-down experiments by Yu et al. [9]
described PTPIP51 to interact with Raf-1 through
14-3-3 thereby modulating cellular motility and mor-
phology via the mitogen activated protein kinase
(MAPK) cascade.
Data available so far implicate that PTPIP51 is
involved in cellular differentiation, motility, cytoske-
leton formation, and in apoptosis. These cellular
alterations in the epithelium and stroma are implicated
in benign prostate hyperplasia (BPH) pathogenesis [10]
and the pathogenesis of prostate carcinoma (PCa)
essentially results from an aberrant regulation of
proliferation and differentiation. Therefore we investi-
gated the PTPIP51-expression proﬁle in BPH and PCa.
Since PCa is the most common non-cutaneous malig-
nancy in men and second leading cause of cancer-
related deaths [11–13] and BPH is the most common
condition associated with ageing in men and often
presents with lower urinary tract symptoms such as
voiding dysfunction or irritability of the bladder [14], it
is certainly of interest to investigate the potential role of
PTPIP51 in the pathogenesis of these disorders.
So far the etiology of PCa is not well understood. It is
discussed to arise with an intermediate state of
proliferative inﬂammatory atrophy (PIA) [15–17] and
prostatic intraepithelial neoplasia (PIN) [18].
The capability of PCa to spread beyond its capsule
along nerve ﬁbers is of great importance since the
perineural invasion (PNI) is the most common reason
of tumor progression [19].
The adhesion of nerve ﬁbers to tumor cells lowers
the amount of apoptosis in cancer cells [20,21]. Up to
now the process of tumor spreading through the neural
capsule and adhering to the nerve ﬁbers is not precisely
known.
Epigenetic changes are involved in the regulation of
expression of many oncogenes and tumor suppressor
genes which contribute to the development and
progression of many somatic tumors including pro-
state cancer. In particular, the role of DNAmethylation
in oncogenesis is well established for many tumor
entities. DNA methylation refers to the addition of
methyl (CH3)-group at the C-5 position of the cytosine
ring in the DNA, which is catalyzed by DNA
methyltransferases (DNMTs).Methylcytosine residues
are often found in short stretches of CpG-rich regions
(e.g., CpG islands) that are mostly unmethylated and
found in the 50 region of approximately 60% of genes
[22].
Methylation of CpG islands within the promoter
region strongly correlates with the transcriptional
activity of particular genes. Both hypo- and hyper-
methylation can lead to chromosomal instability, gene
silencing, or gene overexpression. Those epigenetic
aberrations have been implicated in a variety of
human malignancies, including prostate cancer [23].
We therefore investigated CpG methylation in the
promoter region of PTPIP51 as a possible mechanism
underlying PTPIP51-dependent cell proliferation
during carcinogenesis.
BPH,predominantly involving the stromal compart-
ment of the prostate, is one of the most common
condition associated with the ageing male [24,14]. In
the United States of America over 80% of men aged
50 years and older are affected, resulting in lower
urinary tract symptoms such as bladder outlet obstruc-
tion [25]. So far, there is no solid understanding of
the pathogenesis of this disorder. Recent studies have
discussed the inﬂuence of transforming growth factor-
b (TGF-b), ﬁbroblast growth factor (FGF), and insulin-
like growth factor (ILGF) family members, estrogen/
androgen balance, inﬂammatory processes, and the
theory of ageing [26–29].
Our study aimed to elucidate the possible involve-
ment of PTPIP51 in the pathogenesis of BPHandPCa as
both are present with a high incidence in men.
MATERIALSANDMETHODS
Tissue and Section Preparations
The tissue microarray was constructed using 26
formalin-ﬁxed samples (Ø 4mm), all taken from radical
prostatectomy, 13 resembling PCa and 13 BPH. All
samples were obtained from the Department of Pathol-
ogy, Justus-Liebig-University Giessen. This study was
approved by the ethics commission of the Medical
Faculty, Justus-Liebig-University Giessen.
The PCa samples were reviewed according to the
TNM-classiﬁcation and Gleason score. BPH was
identiﬁed by its localization and by means of histo-
pathological analysis.
For immunohistochemistry, parafﬁn-sections of
4 mm thickness were cut, dried, deparafﬁnized in
xylene, and rehydrated in graded alcohol. Prior to the
staining procedure, antigen retrieval usingmicrowave-
oven heating (2 5min, 800W) in 10mM standard
sodium citrate buffer (pH 6.0) was carried out for all
antibodies used in this study.
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For sodium bisulﬁte sequencing, real-time quanti-
tative polymerase chain reaction (PCR) and reverse
transcription-PCR (RT-PCR), respectively, DNA and
RNAwas obtained from cryo-preserved tissue samples
of 5 BPH and 5 PCa from patients who underwent
prostatectomy at the Department of Urology and
Pediatric Urology, University of Giessen.
Immunohistochemistry
Prior to immunostaining non-speciﬁc binding sites
were blocked with phosphate-buffered saline (PBS)
containing 5% bovine serum albumin and 5%
normal goat serum. Indirect immunoﬂuorescence was
performed by overnight incubation with primary
antibodies (see Table I), diluted in PBS at room
temperature, followed by washing in PBS and sub-
sequent incubation for 1 hr at room temperature with
the appropriate secondary antibodies (see Table I).
Then the slides were washed in PBS, coverslipped in
carbonate buffered glycerol at pH 8.6.
The polyclonal antibody against PTPIP51, raised as
described and characterized in previous studies [3,8],
was used in a 1:400 dilution for ﬂuorescence immuno-
histochemistry.
Primary antibodies were visualized by Alexa ﬂuor
488 and Alexa ﬂuor 555 secondary antibodies. For each
series of antibody staining sections were incubated
with medium lacking PTPIP51 antibody, serving as an
internal negative control. Nuclei were displayed by
Dapi.
The Axioplan 2 ﬂuorescence microscope equipped
with Plan-Apochromat objectives (Carl Zeiss, Jena,
Germany) was used for photographic documentation.
For visualization of the secondary antibodyAlexa ﬂuor
555 an excitation ﬁlter with a range of 530–560 nm and
anemissionﬁlterwith a range572.5–647 nmwereused.
Alexa Fluor 488 was visualized by an excitation ﬁlter
with a range of 460–500 nm and an emission ﬁlter with
a range of 512–542 nm.
Hematoxyline and Eosin (H&E) and
Masson^Goldner Staining
The histomorphological characteristics were eva-
luated by H&E staining. Collagens of the extracellular
tumor matrix were demonstrated byMasson–Goldner
staining.
After evaluation of the immunostained samples,
the coverslips of each slide was removed and
the sections were stained with H&E and evaluated by
light microscopy.
In SituHybridization
In situ hybridization was performed as described
previously [30] using a stringency to achieve hybridiza-
tion only with a homology greater than 80%. Brieﬂy,
5 mm sections were partially digested with proteinase
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TABLE I. AntibodiesApplied forThis Study
Immunogen Antibody source Clone Dilution Manufacturer
PTPIP51: Human cDNA sequence
encoding amino acids 131–470 of
PTPIP51
Rabbit polyclonal 1/400 Prof. HW Hofer, Biochemical
Department, University of
Konstanz, Germany
PGP9.5: Native, from brain Mouse monoclonal 31A3 1/100 Biotrend, Germany, Cat
#BT78-6310-04
a-Smooth muscle-FITC: N-terminal
synthetic decapeptide of a-smooth
muscle actin
Mouse monoclonal 1A4 1/500 Sigma, Germany, Cat #F 3777
CK-Pan: Puriﬁed human callus
cytokeratins
Mouse monoclonal 80 1/40 Acris, Germany, Cat #BM2300
PCNA: Recombinant rat PCNA Mouse monoclonal PC10 1/100 BioLegend, USA, Cat #307902
Anti PTP1B: Human recombinant
protein tyrosine phosphatise
1B (PTP1B)
Mouse monoclonal AE4-2J 1/40 Calbiochem, Germany, Cat
#PHO2
c-Src: Against full-length recombinant
c-Src of human origin
Mouse monoclonal 17AT28 1/100 Santa Cruz, USA, Cat #sc-
130124
Raf-1: C-terminus Mouse monoclonal E-10 1/100 Santa Cruz, USA, Cat #sc-7267
14-3-3b: C-terminus of 14-3-3b
of human origin
Mouse monoclonal A-6 1/100 Santa Cruz, USA, Cat #sc-
25276
Alexa ﬂuor 555 Goat 1/800 Invitrogen, USA, Cat #A21428
Alexa ﬂuor 488 Goat 1/800 Invitrogen, USA, Cat #A11029
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K, post-ﬁxed in 4% paraformaldehyde, and exposed to
20% acetic acid. After prehybridization in 20%
glycerol, sections were covered with the DIG-labeled
sense or antisense cRNA-probes. Production of DIG-
labeled cRNA-probes was performed as described
previously [30]. PCR conditions were 1 948C for
3min, 35 948C for 30 sec, 668C for 30 sec, 728C for
60 sec, and 1 728C for 8min using 50-GTCTCTC-
ACCTGAGCTGGCTAGA-30 as forward primer and
50-GGATAGCCAAATCCTCCTTCGTGA-30 as reverse
primer. The 247 nucleotide ER-product (nt positions
1126–1372, corresponding to aa 376–457) of the human
PTPIP51 gene was subcloned in pGEM-T (Promega,
Heidelberg, Germany). Plasmids were transformed in
the XL1-Blue E. coli strain (Stratagene, Heidelberg,
Germany) and extracted by column puriﬁcation
(Qiagen, Hilden, Germany). In vitro transcription of
DIG-labeled PTPIP51-cRNA was performed using
the 10 RNA-DIG Labeling-Mix (Roche, Mannheim,
Germany) and RNA-polymerases T3 and SP6. Vectors
containing the PTPIP51 insertswere digestedwithNcoI
and NotI (New England Biolabs, Frankfurt, Germany)
for theproduction of sense-cRNAandantisense-cRNA,
respectively. Both cRNAs were used in a dilution of
1:100 (the optimal concentration was determined by a
dot blot test) in hybridization-buffer containing 50%
deionized formamide, 10% dextran sulphate, 2 saline
sodium citrate (SSC), 1Denhardt´s solution, 10 mg/ml
salmon sperm DNA, and 10 mg/ml yeast t-RNA.
Hybridization was performed overnight at 378C in a
humidiWed chamber containing 50% formamide in
2 SSC. Post-hybridization washes were performed
according to Lewis andWells [31]. After blocking with
3% bovine serum albumin, the sections were incubated
(overnight at 48C) with the anti-DIG Fab-antibody
conjugated to alkaline phosphate (Roche). Stainingwas
visualized by developing the sections with nitrobluete-
trazolium/5-bromo-4-chloro-3-indolylphosphate in a
humidiﬁed chamber protected from light. Alterna-
tively, the sections were incubated with anti-DIG
-ﬂuorescein, Fab fragments (Cat# 11 207 741 910,
Roche). For each test negative controls were performed
using DIG-labeled cRNA sense-probes.
RNAExtraction
RNA extraction from cryomaterial was performed
using the RNA extraction kit RNeasy MINI (Qiagen)
according to the manufacturer’s instructions.
First Strand Synthesis
First strand synthesis was performed using Omni-
script (cryomaterial), according to the manufacturer’s
protocol (Qiagen).
ReverseTranscription-PolymeraseChain
Reaction (RT-PCR)
RT-PCR was performed on an iCycler using SYBR
Green Supermix (BioRad, Munich, Germany) to visua-
lize the respective amplicons [32]. Per sample 2 ml
cDNA were used. Cycling conditions were 948C for
2min, followed by 40 cycles of 948C (PTPIP51); 588C
(PTP1B); 638C (c-Src); 63.58C (Raf-1) for 30 sec, 558C for
30 sec, and 728C for 2min. The following primers
were employed: for PTPIP51 as forward primer 50-
AGGGCATCTCGAAACGCATCCA-30 and as reverse
primer 50-CTTCTAGTTCTTCCAGGTCTTTTTG-30,
for PTP1B as forward primer 50-GGAGATGGAAAAG-
GAGTTC-30 and as reverse primer 50-TGCTTTT-
CTGCTCCCACAC-30, for c-Src as forward primer
50-ATGGTGAACCGCGAGGTGCT-30 and as reverse
primer 50-GATCCAAGCCGAGAAGC-CGGTCTG-30,
for Raf-1 as forward primer 50-CAGC-CCTGTCCAG-
TAGC-30 and as reverse primer 50-GCC-TGACTT-
TACTGTTGC-30.
PCR products were visualized by agarose gel
electrophoresis. While ampliﬁcation of a 90 bp b-actin
product served as positive control, negative controls
included samples lacking reverse transcriptase.
Real-Time PolymeraseChain Reaction
(Real-TimePCR)
The ampliﬁcation of cDNA from ﬁve BPH and ﬁve
PCa samples was carried out in 25 ml reaction volume
on the iCycler iQ Real-Time PCR Detection System
(BioRad, Munich, Germany). The ﬁnal reaction tube
contained 100 nM PTPIP51 primers and reference
genes b-actin (forward 50-TTCCTTCCTGGGCATG-
GAGT-30; reverse 50-TACAGGTCTTTGCGGATGTC-
30), HSPCP (forward 50-AAGAGAGCAAGGCAAA-
GTTTGAG-30; reverse 50-TGGTCACAATGCAGCAA-
GGT-30), ATP5b (forward 50-TCACCCAGGCTGGTT-
CAGA-30; reverse 50-AGTGGCCAGGGTAGGCTGAT-
30), 12.5 ml iQSYBRGreenSupermix (BioRad) and2 ml of
DNA template. The PCR conditions were 948C for
3min followed by 40 cycles for 30 sec, 608C for 30 sec,
and 728C for 1min. Melting curves were generated for
both genes after ampliﬁcation. Negative controls were
included in each run. The selection of appropriate
combination of reference genes for expression analysis
of PTPIP51 inPCaandBPH tissuewas carried outusing
NormFinder Program. PCR-products were additional
electrophoresed on a 3% agarose gel and visualized by
GelRed reagent.
Methylation
From10patients (seeTable II)whounderwent radical
prostatectomy, 5 PCa samples, in which at least 70% of
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the cells represented cancer epithelial cells, and 5 BPH
samples were selected for this study. Additionally, the
expression of the tumor epithelial cell marker a-
methylacyl-CoA racemase (AMACR) was determined
to differentiate between PCa and BPH. For DNA
methylation analysis, genomic DNA was isolated from
frozen tissue sections using Qiamp DNA Mini Kit
(Qiagen).
Genomic DNA (2 mg) was treated with sodium
bisulﬁte using EpiTect Bisulﬁte Kit (Qiagen) according
to manufacturer’s instructions. Sodium bisulﬁte con-
verts unmethylated cytosines to uracils, whereas
methylated cytosines remains unaffected. Bisulﬁte-
treated DNA was subsequently ampliﬁed using pri-
mers speciﬁc for bisulﬁte converted DNA: forward 50-
GAAATGGAGG-TTTGGTTGT-30, reverse 50-CCT-
AACAAAAAATCC-ACTCAAA-30. These primers
allow the ampliﬁcation of both the methylated
and the unmethylated alleles by spanning a region
of 341 bp with 18 differentially methylated CpG
nucleotides.
DNA was ampliﬁed in a 30 ml volume containing
10 ml of the extracted and bisulﬁte-treated DNA, PCR
buffer gold, 1.5mM MgCl2, 0.2mM of each dNTP,
0.66 mM of each primer, and 0.5 ml (2.5U) of Amplitaq
Gold polymerase (Qiagen). After activation of the
polymerase at 958C for 10min, DNA was ampliﬁed in
40 cycles for 45 sec at 95, 56, and728C followedby aﬁnal
extension at 728C for 10min. Five milliliters of each
PCR product was analyzed on agarose gel and the
remaining 25 ml were puriﬁed using QIAquick Puriﬁ-
cation Kit (Qiagen). The probes were then subjected
to sequencing using forward primer by Scientiﬁc
Research and Development GmbH, Oberursel,
Germany. The sequencing results were analyzed using
BiQ Analyzer, a software tool for DNA methylation
available by free download from http://biq-analyzer.
bioinf.mpi-inf.mpg.de/.
RESULTS
This study demonstrates for the ﬁrst time the
cell-speciﬁc expression of PTPIP51 mRNA and
protein in BPH and PCa. Furthermore, this is also the
ﬁrst report providing methylation analysis of BPH
and PCa CpG islands in the promoter region of
the PTPIP51 gene as a potential mechanism underly-
ing aberrant expression of PTPIP51 mRNA and
protein level in prostate cancer. Expression of the
PTPIP51 in vitro interaction partners PTP1B, c-Src,
and Raf-1 was demonstrated by RT-PCR. Immu-
nohistochemical experiments revealed a co-expres-
sion with these in vitro interaction partners in BPH
and PCa.
Expression Prof|le of PTPIP51in BPHand
PCa Samples
Quantitative real-time PCR analysis. PTPIP51 ex-
pression levels of ﬁve BPH and ﬁve PCa samples were
assessed by real-time quantitative PCR. Candidate
reference genes for normalization and the best
combination of two genes was calculated according to
their expression stability by the NormFinder program.
The best combination of two genes was b-actin and
HSPCP, which improved the stability value of 0.026,
indicating a more reliable normalization.
Results of expression analysis showed slightly
elevated levels of PTPIP51 in the group of PCa when
compared with the group of BPH (Fig. 1A). Analyzing
each sample of BPH we could observe lower levels of
PTPIP51 expression in three out of ﬁve patients while
in the PCa group all samples represented equally
increased expression (Fig. 1B).
In situ hybridization. PTPIP51 mRNA was detected
inprostatic epithelia of BPH (Fig. 2A) and in tumor cells
of PCa (Fig. 2C). Endothelial cells and smooth muscle
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TABLE II. HumanProstateTissue Samples
Sample
Histological
diagnosis Age
Preoperative
PSA value
Gleason
score PTNM staging
1 PCa 72 15mg/ml 7 pT4 G3 pN1 pR0
2 PCa 70 17mg/ml 9 pT4 G3 pN0 pR1
3 PCa 67 — 7 pT4 G3 pN0 pR1
4 PCa 67 — 7 pT3a G3 pN0 pR0
5 PCa 64 — 6 pT3a G3 pN0 pR1
6 BPH 64 — 7 pT3a G3 pN0 pR1
7 BPH 72 6.15 mg/ml 7 pT4 G3 pN0 pR0
8 BPH 75 18.66mg/ml 6 pT2c G2 pN0 pR0
9 BPH 67 — 5 pT3a G3 pN0 pR0
10 BPH 64 — 6 pT3a G3 pN0 pR0
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cells of vessels in BPH and PCa and immune cells
inﬁltrating the BPH stroma strongly expressed
PTPIP51 mRNA.
Immunhistochemical detection of PTPIP51 in BPH
and PCa. Immunohistochemical staining revealed
PTPIP51 expression in both epithelial cells of prostatic
glands and in prostatic stromal cells of BPH and PCa. A
stronger expression of PTPIP51 protein was present in
ganglia andnerveﬁbers, in immune cells and in smooth
muscle and endothelial cells of vessels.
Comparing the PTPIP51 protein levels in BPH and
PCa, a stronger expression was seen in PCa as the PCa
samples exhibit an increased quantity of ganglia and
nerve ﬁbers, all positive to PTPIP51 antibody.
* Epithelia: BPH prostatic epithelia (Fig. 3) and PCa
tumor cells (Fig. 4), respectively, identiﬁed by
co-staining with a pan cytokeratin antibody,
displayed a faint staining intensity for PTPIP51
protein within the cytoplasm. Occasionally, the
plasma membrane reacted strongly with the
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Fig. 1. Real-timePCR analysis of PTPIP51inBPHandPCa.A: Effectofnormalization approaches on the expression levels of PTPIP51gene in
malignant (PCa) and non-malignant (BPH) prostate tissue samples.Normalizations weremade using reference genes as indicated byNorm-
Finderwithb-actin andHSPCPas thebestcombinationof tworeferencegenes.B:Gels showingexpression levels ofPTPIP51ineach sample of
benignprostatehyperplasia (BPH;1^5)andprostatecarcinoma(PCa;1^5)asassessedbyreal-timePCRanalyzes.Amplificationofb-actinand
HSPCPwasusedascombinationofreferencegenes.Negative control (N).
Fig. 2. PTPIP51insituhybridizationofBPHandPCa.A:Antisense
probe of BPH. Arrowhead: prostatic epithelia.B: Sense probe of
BPH. Arrowhead: prostatic epithelia.C: Antisense probe of PCa.
Arrowhead:tumorcells.D: SenseprobeofPCa.Arrowhead:tumor
cells. Bar: 50mm. Arrow, endothelial cells; double-arrow, immune
cells.
Fig. 3. ImmunostainingofPTPIP51inBPH.A:PTPIP51.B:CK-Pan.
C: PTPIP51. D: a-smooth muscle actin. E: PTPIP51. F: H&E.
Bar: 50mmArrowhead,prostaticepithelia; arrow,endothelialcells;
double-arrow, immune cells; double-arrowhead, smooth muscle
cells; asteric,nerve.
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antibody to PTPIP51 antigen. These cells were
found to be quiescent, as no co-expression
with proliferating cell nuclear antigen (PCNA),
a proliferation marker, was detected (data not
shown).
* Stroma: Smooth muscle cells, identiﬁed by co-
expression with a-smooth muscle actin, and
ﬁbroblasts comprising the prostatic stroma of
BPH (Fig. 3) and PCa (Fig. 4) both reacted positive
with the PTPIP51 antibody.
* Neuronal tissue: PTPIP51 protein was detected in a
higher concentration in the supplying nerve ﬁbers
and in the ganglia of the autonomous nerve
system as identiﬁed by co-expression of PGP9.5, a
neuronal marker (Fig. 4).
* Immune cells: A strong immune reaction with
the antibody to PTPIP51 was detected in the
cytoplasm of immune cells (e.g. lymphocytes,
granulocytes, and plasma cells), present in BPH
(Fig. 3) and PCa (Fig. 4).
* Vessels: Endothelial cells lining venous and
arterial microvessels and capillaries, were also
PTPIP51 positive. Lumina of the vessels, packed
with granulocytes and lymphocytes displaying a
strong PTPIP51 labeling, were detected quite
frequently (Figs. 3 and 4).
Analysis of PTPIP51 promotor methylation in BPH
and PCa samples. In the BPH group one out of ﬁve
samples was completely methylated. Two out of
ﬁve samples displayed methylation of 14 CpGs. In
those patients, loss ofmethylationwas observed in four
CpGs. Interestingly, differential methylation was
observed in CpGs at positions 1–9. CpGs 10–18 were
hypermethylated in all ﬁve samples. Analysis of the
PCa group revealed that similarly to BPH samples,
CpG positions from 10 to 18 weremethylated in all ﬁve
out ﬁve PCa samples, however, in the PCa group a
signiﬁcant decrease of methylation could be observed
in CpGs at positions 1–9 when compared to the
BPH group. Nine out of 18 CpGs were indicated as
unmethylated in a single PCa sample. Two PCa
samples had more than 7 unmethylated CpGs and a
single sample displayed methylation of 15 CpGs.
Furthermore, aggregated representation of methyla-
tion data from the PCa and BPH groups showed that
three CpGs (2, 8, and 9) were entirely unmethylated in
PCa while the BPH group had no CpG that was
unmethylated in each sample. In contrast to the PCa
group, the BPH group displayed 13 completely
methylated CpG positions (Fig. 5).
Expression Prof|le of the InVitro Interaction
Partners of PTPIP51
RT-PCR analysis. The mRNA expression of PTPI-
P51and its in vitro interaction partners was tested by
RT-PCR. As demonstrated in Figure 6 both BPH and
PCa express considerable amounts of PTP1B, c-Src, and
Raf-1. b-actin ampliﬁcation served as an internal
positive control. Probes lacking reverse transcriptase
served as negative controls.
Cellular distribution. Double labeling studies with
antibodies to PTPIP51 antigen and the following
in vitro interaction partners Src kinase and Raf-1,
which take part in the MAP kinase pathway, 14-3-3b
and PTP1B revealed different co-expressions patterns.
* PTP1B (Fig. 7A–D): PTP1B was partially co-
expressed with PTPIP51 in prostatic epithelial
cells (BPH) and in tumor cells (PCa). In BPH and
in PCa a subset of immune cells co-expressed
both antigens. In endothelial cells co-expression
of both antigens was restricted to PCa samples.
* C-Src (Fig. 7E–H): c-Src was partially co-
expressed with PTPIP51 in prostatic epithelial
cells (BPH) and in tumor cells (PCa). In endothe-
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Fig. 4. ImmunostainingofPTPIP51inPCa.A:PTPIP51.B:CK-Pan.
C: PTPIP51.D: PGP9.5.E: PTPIP51.F:H&E.Bar: 50mmArrowhead,
tumor cells; arrow, endothelial cells; double-arrow, immune cells;
asteric,nerve.
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lial cells a faint co-expression of both antigens
could be found in PCa samples.
* Raf-1 (Fig. 7I–L): Raf-1 was co-expressed with
PTPIP51 in the basal part of prostatic epithelial
cells (BPH) and in the apical part of tumor cells
(PCa). In BPH and in PCa stromal smooth muscle
cells, endothelial cells and a subset of immune
cells co-expressed both antigens.
* 14-3-3b (Fig. 7M–P): 14-3-3b was co-expressed
with PTPIP51 in the apical part of the prostatic
epithelia (BPH). Tumor cells of PCa displayed
a faint staining for both antigens. A stronger
expression of both antigens could be found in a
subset of immune cells in BPH and PCa.
DISCUSSION
To our knowledge, this study demonstrates for
the ﬁrst time the mRNA expression and cellular
localization of PTPIP51 protein in BPH and PCa.
Promoter methylation status of PTPIP51 is aberrant in
prostate cancer when compared to BPH, this might
explain the elevated expression of PTPIP51 in PCa.
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Fig. 5. Methylation profile of PTPIP51gene promoter in BPH and PCa using sodium bisulfite sequencing.Methylation pattern of five BPH
and five PCa samples. Black circles correspond to methylated CpGs, open circles correspond to unmethylated CpGs. Bar diagram
demonstrates aggregatedrepresentation ofmethylation data of everyCpGnucleotidewithin theDNA fragmentof the BPHand PCa group.
FiguresweregeneratedusingBiQAnalyzerMethylation tooldownloadfromhttp://biq-analyzer.bioinf.mpi-inf.mpg.de/.
Fig. 6. ExpressionofPTPIP51andits invitro interactionpartners
as detected by RT-PCR. RT-PCR was performed using primers
specific to PTPIP51,PTP1B, c-Src, andRaf-1as given inMaterials and
Methods Section.b-Actinwas amplifiedas aninternalpositive con-
trolandprobeslackingreversetranscriptaseservedasnegativecon-
trols (N). Samples of benign prostate hyperplasia (BPH; 1^5),
samplesofprostate carcinoma(PCa;1^5).
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We demonstrated the expression of PTPIP51 in
prostate cancer and in BPH within different tissues
comprising tumor and peritumoral environment and
epithelial and stromal cells of the prostate, respectively.
Nerve ﬁbers, immune cells, and vessels displayed
a strong immune reaction. Notably, epithelial cells
displayed a membranous staining pattern with the
PTPIP51 antibody, indicating a putative involvement
in the regulation of cell–cell interactions. The latter are
known to play a key role in normal and abnormal
growth of BPH and PCa [33–35]. A similar subcellular
localization of PTPIP51 in keratinocyte carcinomas
epithelial cells of non-melanoma skin cancer has been
observed recently [6].
In the healthy prostate, interactions of nerves,
stromal and epithelial cells play an important role
during its development and are relevant for the
physiological function of the adult prostate [36,37].
Denervation experiments of the rat prostate resulted in
morphological and functional changes of the prostatic
glandules, indicating that besideshormonal regulation,
the nerval innervation might play a crucial role for the
development and functional integrity of the prostate
[38,39]. The autonomous innervation of the prostate is
organized in the way that prostatic epithelia receives a
cholinergic type of innervation while stroma receives a
predominantly noradrenergic innervation [40–42].
As PTPIP51 is expressed in both PCa and BPH
ganglia and nerve ﬁbers, PTPIP51 might play a role for
the functional integrity of the prostatic autonomous
nervous system, accordingly essential for the prostatic
development and function.
In prostate cancer nerve ﬁbers play an important
role, amongst others being responsible for tumor
spreading and supporting tumor growth. PNI, driven
by the interaction of nerves and tumor cells is a process
generally described for prostate cancer, but was also
observed in bile duct, pancreatic, head, and neck
cancers [19]. PNI is present in more than 85% of PCa
[42] and appears to be important for the invasiveness of
the tumor. Tumor spreading along nerve ﬁbers is the
most common way of tumor spreading.
Our results displayed that all ganglia and nerve
ﬁbers of the prostate show a strong expression of
PTPIP51 protein in PCa as well as in BPH. Compared
with BPH, a stronger expression of PTPIP51 protein in
prostate cancer was observed. Corresponding results
were observed for the mRNA levels of PTPIP51,
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Fig. 7. Co-immunostainingofPTPIP51anditsinvitrointeractionpartners.Samplesofbenignprostatehyperplasia(BPH)A,B,E,F,I,J,M,and
N. Samplesofprostatecarcinoma(PCa)C,D,G,H,K,L,O, andP,arrowhead:tumorcells.Bar: 20mm.Arrow,endothelialcells;double-arrow,
immunecells; asteric,nerve.
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displaying an overexpression in the PCa group. This
ﬁnding could be explained by the observations made
by Ayala et al. [19] who reported cancer-related
axonogenesis andneurogenesis leading to an increased
nerve density in PCa.
Elevated expression levels of PTPIP51 in PCa and
BPH might be explained by data of the methylation
analysis of CpGs within the promoter region of
the PTPIP51 gene. In general, methylation is associated
with gene silencing [43], lack of methylation in
contrast is responsible for decondensation of chromatin
genomic instability and may cause activation of
retrotransposon elements resulting in aberrant over-
expression of certain genes [44,45].
Therefore, methylation of ﬁve BPH and ﬁve PCa
samples, parallel with the mRNA and protein expres-
sion of PTPIP51 were analyzed in this study. Eighteen
CpGs were characterized from each sample using
sodium bisulﬁte sequencing. In BPH samples almost
the entire investigated region consisted of methylated
CpGs. At least 78% (14 of 18) CpGs were methylated.
In PCa, a loss of methylation in the CpG positions 1–3,
5–6, 8–9 was observed. This is the ﬁrst study present-
ingdifferences in the PTPIP51 genemethylation of PCa.
Overexpression of PTPIP51 as a result of CpG island
hypomethylation might be a potential factor contri-
buting to PNI of prostate cancer, as DNA hypomethly-
tion was reported to occur late in prostate
carcinogenesis [46].
The reduction of 50-methylcytosine content in the
genome occurs late in prostate cancer progression,
appearing only in the stage of metastatic disease. Even
though this study includes only ﬁve PCa samples with
Gleason score between 7 and 9 and ﬁve BPH samples,
we were able to demonstrate differences in CpG
methylation of the PTPIP51 gene promoter. Under-
standing DNA methylation/demethylation of the
PTPIP51 gene in more detail may shed new light on
the involvement of PTPIP51 in the carcinogenesis and
may help to understand PNI of prostate cancer cells.
Chronic inﬂammation of the prostate is presumed to
be involved in prostate growth either in hyperplastic
(BPH) or neoplastic (PCa) changes [47].
Epidemiologic data suggest a high percentage
of BPH samples displaying signs of chronic inﬂamma-
tion [48,49]. Inﬂammation is thought to incite carcino-
genesis by causing cell and genome damage,
promoting cellular turnover, and creating a tissue
microenvironment that can enhance cell replication,
angiogenesis, and tissue repair [50].
Recent publications also support the hypothesis that
inﬂammation is a possible factor inducing transition
from BPH to PCa [51].
As cells of the innate and adaptive immune system
in blood vessels, in lumina of glandules, and also
inﬁltrating the stroma of BPH andPCa reacted strongly
positive to PTPIP51 antibody an involvement of
PTPIP51 in inﬂammatory processes seems very likely.
For tumor growth and spreading, the formation of
new blood capillaries is essential. Vascular endothelial
growth factor (VEGF) is a potent angiogenic peptide
effecting in the regulation of hematopoietic stem cell
development, extracellular matrix remodeling, and
inﬂammatory cytokine regeneration [52,53]. VEGF
has been shown to be expressed in glandular and
surrounding stromal cells, regulated by androgens.
They are crucial for normal prostate growth and
development, as well as for the development of BPH
andPCa.Androgendeprivation resulted in adecreased
expression of VEGF by prostate cancer [54]. Expression
analyses of peptide growth factors made by Soulitzis
et al. [55] showedVEGF to be overexpressed in prostate
cancer, while there was a downregulation in BPH.
Since PTPIP51 is strongly expressed in endothelial cells
of the tumor environment, we suggest PTPIP51 to play
a role in the process of angiogenesis. This is further
supported by the fact that Src-kinase can increase the
expression of VEGF through the JaK1–STAT3–VEGF
pathway. Apart from that an interaction of Src with
steroid receptors was reported. It was shown that low
amounts of androgen receptors can lead to an increased
Src activation in the cytoplasm [56]. Since Src is
partially co-localized with PTPIP51 and PTPIP51 is
tyrosine-phosphorylated by c-Src and v-Src in vitro [2]
a possible role of PTPIP51 in angiogenesis is likely.
In prostate cancer and in other malignancies
increased activity or expression of Src-kinase and other
Src family kinases (SFKs) has been reported. SFK-
activated pathways are known to be involved in
cell growth, tumor adhesion, motility, invasion, and
angiogenesis [57]. Therefore, the SFK/Abl inhibitor,
dasatinib, is currently being investigated as a new
treatment option inprostate cancer and invarious other
malignancies [58].
CONCLUSIONS
In summary, PTPIP51 is expressed in both, BPH
and PCa. Interestingly, PCa samples displayed a
higher concentration of PTPIP51 mRNA and protein,
compared to BPH samples. These results might be
explained by the hypomethylation of the PTPIP51
promoter.
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Summary. Glioblastoma multiforme (GBM) is the most
common and most malignant primary brain tumour.
Protein tyrosine phosphatase interacting protein 51
(PTPIP51) is an interaction partner of 14-3-3ß, which
correlates with the grade of malignancy in gliomas. In
this study PTPIP51 and its interacting partners 14-3-3ß,
PTP1B, c-Src, Raf-1 as well as EGFR were investigated
in human glioblastoma. 
Twenty glioblastoma samples were analyzed on
transcriptional and translational level by immunohisto-
chemistry, in situ hybridization and RT-PCR. To
compare PTPIP51 expression in gliomas of different
malignancies, quantitative RT-PCR for grade II
astrocytoma and GBM samples was employed.
Additionally, we analyzed the correlation between
PTPIP51 and 14-3-3ß transcription, and checked for in
situ interaction between PTPIP51 and 14-3-3ß and
PTP1B, respectively.
PTPIP51 and 14-3-3ß mRNA showed a tumour
grade dependent upregulation in gliomas. Glioblastoma
cells displayed a strong immunoreaction of PTPIP51,
which co-localized with 14-3-3ß and PTP1B. The
duolink proximity ligation assay corroborated a direct in
situ interaction of PTPIP51 with both proteins, known to
interact with PTPIP51 in vitro. The in vitro interacting
partners Raf-1 and c-Src showed a partial co-
localization. Besides, immune cells located in capillaries
or infiltrating the tumour tissue and endothelial cells of
pseudoglomerular vessels revealed a high PTPIP51
expression. 
The upregulation of PTPIP51 and its connection
with the EGFR/MAPK pathway by 14-3-3ß via Raf-1
and by PTP1B via c-Src, argue for a functional role of
PTPIP51 in the pathogenesis of human glioblastoma.
Key words: Glioblastoma, PTPIP51, 14-3-3ß, EGFR,
MAPK, Raf-1, Glioma
Introduction
The incidence of gliomas is increasing worldwide.
18,820 new cases of human primary central nervous
system tumours are diagnosed annually in the United
States of America, about 60% are gliomas and 30-40%
of these account for glioblastoma (GBM) (Khan et al.,
2009). GBM is the most frequent and most malignant
form of neuroepithelial tumour. The mean survival time
of GBM patients is still around one year, despite
significant advances in therapeutic options (McLendon
et al., 2007).
PTPIP51 is a novel protein that has been shown to
be expressed in many human cancers (Lv et al., 2006;
Stenzinger et al., 2009). As demonstrated by Koch et al.
(2008, 2009b) PTPIP51 is expressed in human
keratinocyte carcinomas and prostate cancer. Comparing
benign prostate hyperplasia with prostate carcinoma
provided evidence that PTPIP51 expression is partially
controlled by promoter methylation. Lv et al. (2006)
demonstrated PTPIP51 mRNA-expression in various
carcinomas.
PTPIP51 is evolutionary conserved and was shown
to interact in vitro with the non-transmembrane protein-
tyrosine phosphatase, Protein Tyrosine Phosphatase 1B
PTPIP51, a positive modulator of the MAPK/Erk 
pathway, is upregulated in glioblastoma and 
interacts with 14-3-3ß and PTP1B in situ
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(PTP1B) (Stenzinger et al., 2005, 2009). The protein is
phosphorylated in vitro and in situ at Tyr176 by Src
kinase and dephosphorylated by PTP1B (Stenzinger et
al., 2009). In HEK 293 and HeLa cells, PTPIP51
overexpression was shown to enhance apoptosis (Lv et
al., 2006).
Recently, two independent studies by Jin et al.
(2004) and Ewing et al. (2007) demonstrated the
interaction between the two isoforms 14-3-3ß, 14-3-3γ
and PTPIP51. The study of Yang et al. (2009)
demonstrated a correlation between the grade of
malignancy and the expression of 14-3-3ß and 14-3-3η
in gliomas. In contrast, normal brain tissue was not
found to express these two 14-3-3 isoforms. The
isoforms ß and η belong to a superfamily of 14-3-3
proteins, which are differentially expressed in many
human tissues. 14-3-3 proteins have been implicated in
numerous cellular processes, such as tumourigenesis,
cell cycle control and apoptosis (Cao et al., 2008). 
Yu and co-workers (2008) reported PTPIP51 to
interact with Raf-1 through 14-3-3 protein, thereby
modulating cellular motility and morphology by the
mitogen activated protein kinase (MAPK) cascade. The
MAPK/Erk pathway is involved in a variety of cellular
functions such as growth, proliferation, differentiation,
migration and apoptosis. This pathway has been
extensively studied in glioblastoma cells (Lopez-Gines
et al., 2008). The data available so far consider PTPIP51
to play a role in cellular differentiation, motility,
cytoskeleton formation and apoptosis.
This study primarily aimed to investigate the
PTPIP51-expression profile in GBM, applying RT-PCR,
quantitative real time PCR, in situ hybridization and
immunohistochemistry. Moreover, cell specific co-
expression of the proteins 14-3-3ß, Raf-1, PTP1B, c-Src
and EGFR were assessed at the mRNA and protein level.
Furthermore, the direct interaction of PTPIP51 with 14-
3-3ß and PTP1B in situ was substantiated.
An earlier study by Koch et al. (2009a) displayed the
expression of PTPIP51 to be restricted to neurons in
specific areas of normal mouse brain and glial cells did
not show an expression of PTPIP51. 
Data obtained in the present study will set the base
for further studies that aim to investigate the putative
role of PTPIP51 in glioblastoma formation.
Material and methods
Samples of twenty glioblastoma cases and samples
of four astrocytomas were included in this study (Table
1).
Glioblastoma specimens were stained immuno-
histochemically for PTPIP51, 14-3-3ß, c-Src, Raf-1,
PTP1B, EGFR, apoptosis (TUNEL) and proliferation
(Ki67). The cell specific expression of PTPIP51 was
corroborated by means of in situ hybridization.
Four intraoperatively obtained tissue samples of
primary glioblastoma and one of recurrent glioblastoma
were examined for mRNA expression of PTPIP51, 14-3-
3ß, c-Src, Raf-1 and PTP1B. Moreover, to obtain
quantitative data on the transcriptional activity of the 14-
3-3ß and PTPIP51 gene in grade II astrocytoma (n=4
paraffin embedded samples) and glioblastoma (n=5
paraffin embedded samples) kinetic PCR was employed.
Immunohistochemistry
The tumour tissue was fixed in neutral-buffered
formalin for 48h, embedded in paraffin, sectioned and
stained with H&E. The samples were categorized
according to the WHO classification and diagnosed as
GBM. 
Paraffin samples were obtained from the Institute of
Neuropathology, University Hospital Bonn. The patients
had given informed consent that parts of the histological
specimens can be used for research purposes. The
sections were deparaffinized in xylene and rehydrated in
graded ethanol. Prior to the staining procedure, antigen
retrieval using microwave-oven heating (2x5min, 800W)
in 10mM standard sodium citrate buffer (pH 6.0) was
carried out for all antibodies used in this study.
Nonspecific binding sites were blocked with
phosphate-buffered saline (PBS) containing 5% bovine
serum albumin and 5% normal goat serum. Immuno-
reaction with the primary antibodies (Table 2) was
performed overnight at room temperature, followed by
incubation with the appropriate secondary antibodies
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Table 1. Tumour specimens included in the study Tumours.
Age Sex Localization Tumour WHO-
(years) specimens Grade
1 65 M central, left GBM IV
2 63 F frontal, right GBM IV
3 78 F frontal, right GBM IV
4 72 M fronto-temporal, left GBM IV
5 76 M temporal, right GBM IV
6 70 M central, right GBM IV
7 60 M temporal, right GBM IV
8 66 M temporo-dorsal, left GBM IV
9 72 F temporo-medial, right GBM IV
10 61 M temporo-parietal, left GBM IV
11 42 M central, left GBM IV
12 67 M frontal, right GBM IV
13 78 M central, right GBM IV
14 68 F temporo-polar, left GBM IV
15 52 M precentral/central, left GBM IV
16 33 M temporo-medial, right Astrocytoma II
17 23 F insula, left Astrocytoma II
18 44 F corpus callosum, left Astrocytoma II
19 31 M insula, right Astrocytoma II
20 55 M occipital, left (hemianopsia) GBM magnocellular IV
21 55 F parietal, right GBM IV
22 46 M parietal/pre-central gyrus, left GBM, relapse IV
23 66 M parietal, occipital right GBM, relapse IV
24 76 M Broca region, left GBM IV
No. 1-19 were analyzed by immunocytochemistry and No. 11-19 by
quantitative real time PCR. Tumours No. 20-24 were analyzed by
reverse transcriptase PCR.
(Table 2) for 1 h at room temperature. Subsequently, the
slides were coverslipped in carbonate buffered glycerol
at pH 8.6. 
The polyclonal antibody against PTPIP51 was raised
as described and characterized in previous studies (Koch
et al., 2009a).
Primary antibodies were visualized by Alexa fluor
488 and Alexa fluor 555 secondary antibodies. For each
series of antibody staining sections were incubated with
medium lacking PTPIP51 antibody, serving as an
internal negative control. Nuclei were displayed by
DAPI.
Apoptosis was detected using the in situ cell death
detection kit ApopTag (Chemicon International, USA #
S7110) which employs an indirect TUNEL method,
utilizing an anti-digoxigenin antibody that is conjugated
to a fluorescein reporter molecule. It provides indirect
immunofluorescence staining. Results were analyzed by
using fluorescence microscopy. The kit was used
according to the instructions by the manufacturer.
Immunofluorescence analysis and photo-
documentation were performed on an Axioplan 2
fluorescence microscope equipped with Plan-
Apochromat objectives (Carl Zeiss Jena, Germany).
Visualization of the secondary antibody Alexa fluor 555
was achieved with an excitation filter of 530-560 nm and
an emission filter with a range 572.5-647 nm. Alexa
Fluor 488 was visualized by an excitation filter with
460-500nm and an emission filter 512-542 nm.
Duolink proximity ligation assay (DPLA)
Interaction of PTPIP51 with either PTP1B or 14-3-
3ß was detected by the proximity ligation assay kit
DuoLink (Olink biosciences, Uppsala, Sweden, PLA
probe anti-rabbit minus for the detection of the rabbit
PTPIP51 antibody, Cat.# 90602; PLA probe anti-mouse
plus for the detection of the mouse anti PTP1B or 14-3-
3ß antibody, Cat.# 90701; Detection Kit 563, Cat.#
90134). The DuoLink proximity ligation assay
secondary antibodies only hybridise when the two
different PLA probes (probe anti-rabbit minus and probe
anti-mouse plus) have bound to proteins in proximity
closer than 40 nm. This proximity results in ligation
forming a circular template and amplification step the
fluorophore coupled testing probe binds the amplified
oligonucleotide strands. Addition of the fluorescent
labelled oligonucleotides that hybridize to the rolling
circle amplification (RCA) product leads to a point-
shaped signal that is visible in fluorescence microscopy.
Methanol-fixed air-dried samples were per-
incubated with blocking agent for 1h. After washing in
PBS for 10 min, primary antibodies for PTPIP51 and
PTP1B, or PTPIP51 and 14-3-3ß were applied to the
samples. The antibodies were diluted in the blocking
agent at a concentration of 1:500 and 1:100, respectively.
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Table 2. List of the antibodies used in this study.
Immunogen Antibody Source Clone Dilution Manufacturer
PTPIP51 Human recombinant PTPIP 51 protein encoding
amino acids (aa) 131-470 Rabbit polyclonal 1:400
Prof. HW Hofer, Biochemical
Department, University
Konstanz, Germany
14-3-3 ß Epitope mapping the C-terminus of human origin Mouse monoclonal A-6 1:100 Santa Cruz Cat# sc-25276
PTP1B Human recombinant protein tyrosinephosphatase 1B (aa 1 – 321) Mouse monoclonal 107AT531 1:100 Abgent Cat#AM8411
Glial fibrillary acidic protein Purified porcine glial filament from spinal cord Mouse monoclonal GA5 1:200 Chemicon Cat# MAB3402
Raf-1 Epitope mapping the C-terminus of human origin Mouse monoclonal E-10 1:50 Santa Cruz Cat# sc-7267
c-Src Full-length human recombinant c-Src Mouse monoclonal 17AT28 1:100 Santa Cruz Cat# sc-130124
EGFR Plasma membranes of A431 cells Mouse monoclonal 2E9 1:75 Santa Cruz Cat# sc-57091
Ki67 Human recombinant peptide corresponding to a1002 bp Ki-67 cDNA fragment Mouse monoclonal MIB-1 1:100
Dako Cytomation Cat# M
7240
CD20 CD20 protein Mouse monoclonal B9E9 1:100 Thermo Scientif ic Cat #MA1-7634
CD34 CD34 protein from human endothelial vesicles Mouse monoclonal QBEND-10 1:100 ThermoScientif ic Cat.#Ma35170
Granulocyte marker SPM250 nuclei from Pokeweed nitrogen-stimulatedhuman peripheral blood lymphocytes Mouse monoclonal his48 1:100 Santa Cruz Cat# sc-65523
α-smooth muscle actin- FITC
antibody
N-terminal synthetic decapeptide of α-smooth
muscle actin Mouse monoclonal clone 1A4 1:100 SigmaAldrich Cat# F3777
Alexa fluor 555 Coupled to
anti-rabbit antibody IgG heavy chains from rabbit Goat 1:800 Invitrogen Cat# A21428
Alexa fluor 488 Coupled to
anti-mouse antibody IgG heavy chains from mouse Goat 1:800 Invitrogen Cat# A11029
ApopTag® Fluorescein In
Situ Apoptosis Detection Kit
Chemicon International
S7107
Incubation was done overnight in a pre-heated humidity
chamber. Slides were washed three times in PBS for 10
min. Duolink PLA probes detecting rabbit or mouse
antibodies were diluted in the blocking agent at a
concentration of 1:5 and applied to the slides following
incubation for 2h in a pre-heated humidity chamber at
37°C. Washing three times in PBS for 10 min removed
unbound PLA probes. For hybridization of the two
Duolink PLA probes Duolink Hybridization stock was
diluted 1:5 in high purity water and slides were
incubated in a pre-heated humidity chamber for 15 min
at 37°C. The slides were washed in TBS-T for 1 min
under gentle agitation. The samples were incubated in
the ligation solution consisting of Duolink Ligation
stock (1:5) and Duolink Ligase (1:40) diluted in high
purity water for 90 min at 37°C. Detection of the
amplified probe was done with the Duolink Detection
kit. Duolink Detection stock was diluted 1:5 in high
purity water and applied for 1 h at 37°C. Final washing
steps were done by SCC buffer and 70% ethanol.
H&E
The histomorphological characteristics were
evaluated by hematoxylin and eosin staining. 
In situ hybridization
In situ hybridization was performed as described
previously (Koch et al., 2009a).
Reverse transcriptase-polymerase chain reaction (RT-
PCR)
For assessment of RT-PCR five glioblastoma tissue
specimens were obtained during neurosurgical resection.
The tissue samples were immediately transferred into
RNA-later (Qiagen, Hilden, Germany) and stored deep
frozen at -20°C according to the manufacturer ’s
instructions. All tissue samples used for RT-PCR were
obtained from the Department of Neurosurgery, Justus-
Liebig-University, Giessen. Prior to resection, patients
had given informed consent to using parts of the
histological specimen for research purposes.
The RNA extraction was performed using the RNA
extraction kit RNeasy MINI (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions.
Qualitative reverse transcriptase PCR was performed
on an iCycler using SYBR Green Supermix (BioRad,
Munich, Germany) to visualize the respective amplicons.
2 μl cDNA were used per sample. Cycling conditions
were 94°C for 2 min, followed by 40 cycles of 94°C
(PTPIP51); 58°C (PTP1B); 63°C (c-Src); 63.5°C (Raf-1)
and 60°C (14-3-3ß) for 30 sec, 55°C for 30 sec and 72°C
for 2 min. The primers were employed for PTPIP51,
PTP1B, c-Src, Raf-1 and 14-3-3ß (Table 3).
PCR products were visualized by agarose gel
electrophoresis. While amplification of a 90 bp ß-actin
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Table 3. Primer used for RT-PCR and for quantitative real time PCR.
Primer RT-PCR (fresh tissue specimen) size template
PTPIP51 forward 5´-GCAGGTGGTGCTATCAGGTC-3´ 
reverse 5’-AGCTCCAGGGCCAACTTCATC-3’ 232 BP 1294-1525 
PTP1B forward 5’-GGAGATGGAAAAGGAGTTC-3’ 
reverse 5’-TGCTTTTCTGCTCCCACAC-3’ 311 BP 177-487
14-3-3ß forward 5’-ATTCGTCTTGGTCTGGCACT-3’ 
reverse 5’-CAGGCTACAGGCCTTTTCAG-3’. 78 BP 689-766, 784-861
c-Src forward 5’-ATGGTGAACCGCGAGGTGCT-3’ 
reverse 5’-GATCCAAGCCGAGAAGCCGGTCTG-3’ 244 BP 1753-1996
Raf-1 forward 5’-CAGCCCTGTCCAGTAGC-3’ 
reverse 5’-GCCTGACTTTACTGTTGC-3’ 614 BP 1287-1900
ß-actin forward 5’-TTCCTTCCTGGGCATGGAGT-3’ 
reverse 5’-TACAGGTCTTTGCGGATGTC-3’ 90 BP 2439-2528
Primer quantitative RT-PCR (paraffin embedded tissue)
PTPIP51 forward 5’-TCAAGGAGCATGTGGACAAA-3’ 
reverse 5’-ATAGCACCACCTGCCAAGAA-3’ 80 BP 1228-1307
14-3-3ß forward 5’-ATTCGTCTTGGTCTGGCACT-3’ 
reverse 5’-CAGGCTACAGGCCTTTTCAG-3’. 78 BP 689-766, 784-861
ß-actin forward 5’-TTCCTTCCTGGGCATGGAGT-3’ 
reverse 5’-TACAGGTCTTTGCGGATGTC-3’ 90 BP 2439-2528
GAPDH forward 5’-ATGCCAGTGAGCTTCCCGTTCA-3’ 
reverse 5’-TGGTATCGTGGAAGGACTCATGA-3’ 189 BP 628-794
product served as positive control, negative controls
included samples lacking reverse transcriptase.
Quantitative real time PCR
Five paraffin-embedded GBM tissues and four
samples from patients with grade II astrocytoma were
used for quantification of mRNA. The purification of
RNA was done using the QIAamp DNA FFPE tissue kit
(Qiagen, Hilden, Germany) according to the
manufacturer’s instruction.
The amplification of cDNA was carried out in 25 μl
reaction volume on the iCycler iQ Real-Time PCR
Detection System (Bio Rad, Munich, Germany). The
final reaction tubes contained 100nM as PTPIP51, 14-3-
3ß and reference genes ß-actin and GAPDH (Table 3),
12.5 μl iQ SYBR Green Supermix (Bio Rad) and 2 μl of
DNA template. The PCR conditions were 94°C for 3
min followed by 40 cycles for 30 sec, 60°C for 30 sec
and 72°C for 1min. Melting curves were generated for
both genes after amplification. Negative controls were
included in each run. The selection of appropriate
combination of reference genes for expression analysis
of PTPIP51 in GBM and astrocytoma II tissue was
carried out using NormFinder Program. PCR-products
were additionally electrophoresed on a 3% agarose gel
and visualized by GelRed reagent.
Results
This study demonstrates for the first time the cell-
specific expression of PTPIP51 mRNA and protein in
human glioblastoma. Immunohistochemical experiments
and in situ hybridization revealed a strong expression of
PTPIP51 in GBM tumour cells and endothelial cells and
immune cells. Additionally, the PTPIP51 expression
profile was assayed in apoptosis by TUNEL and in
proliferation with Ki67 by double immunostaining.
Furthermore, we explored the interacting partners of
PTPIP51, 14-3-3ß, Raf-1, PTP1B, c-Src and EGFR. The
transcription of the respective signalling partners was
shown by qualitative reverse transcriptase PCR. The
correlation of the tumour grade of gliomas with the
quantitative expression of both, PTPIP51 and 14-3-3ß,
was examined by quantitative real time PCR comparing
GBM and grade II astrocytoma. 
In situ expression profile of PTPIP51 mRNA and protein
Immunohistochemical staining of 15 GBM samples
revealed PTPIP51 protein expression in tumour cells as
identified by subsequent H&E staining of the sections
(Fig. 1A-C). Probing glioblastoma samples with both
PTPIP51 antibody and GFAP antibody confirmed the
expression of PTPIP51 in malignant glial cells (Fig. 1D-
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Fig. 1. Immunostaining of PTPIP51 in sections of human glioblastoma. A. PTPIP51 immunostaining. B. H&E staining of section A. C. DAPI staining of
section A. D. PTPIP51 immunostaining. E. GFAP staining of section D. F. DAPI staining of section D. Arrows: PTPIP51 positive glioblastoma cells,
arrowheads: PTPIP51 positive endothelial cells, double arrowheads: PTPIP51 and GFAP positive reactive astrocyte, double arrow: PTPIP51 positive
immune cell (neutrophil granulocyte). Bar: 50 μm.
1536
PTPIP51, 14-3-3ß and PTP1B in glioblastoma
Fig. 2. PTPIP51 expression in immune cells, smooth muscle cells and endothelial cells. A. PTPIP51 immunostaining. B. granulocyte marker of section
A. C. Merge of A, B and DAPI. D. PTPIP51 immunostaining. E. B lymphocyte in section D detected by CD20. F. Merge of D, E and DAPI. G. PTPIP51
immunostaining. H. α-sma of section G. I. Merge of G,H and DAPI. J. PTPIP51 immunostaining. K. Endothelial cells detected by CD34 in section J. L.
Merge of J, K and DAPI. Arrowhead: neutrophil granulocytes; blank arrowhead: B lymphocytes; double arrow: smooth muscle cells; arrow: endothelial
cells; white circle: lipofuscin granula . Bars: A-F, 10 μm; G-L, 20 μm.
F). Endothelial cells (Fig. 2J-L), smooth muscle cells
(Fig. 2G-I) and immune cells also showed PTPIP51
expression. In endothelial cells of normal and of
pseudoglomerular vessels PTPIP51 protein was
restricted to the plasmamembrane and to the nucleus.
Granulocytes located in capillary lumina or infiltrating
the tumour, as well as the necrotic tissue, displayed a
strong PTPIP51 immunoreaction (Fig. 2A-C). In contrast
to granulocytes, B lymphocytes did not show any
PTPIP51 expression (Fig. 2D-F). 
Matching the protein expression profile, PTPIP51
mRNA was found in the cytoplasm of tumour cells and
in the cytoplasm of endothelial cells as detected by in
situ hybridization (Fig. 3).
In situ expression profile of PTPIP51 and its interacting
partners
PTPIP51 and 14-3-3ß showed a strict co-
localization. Both proteins were found in glioblastoma
cells, endothelial cells and in immune cells. The
glioblastoma cells displayed a strong cytoplasmic
reaction (Fig. 4A-C). In astrocytoma, a co-localization
for PTPIP51 and 14-3-3ß was seen, but to a much lower
extent (Fig. 4D-F).
To corroborate the interaction of PTPIP51 and 14-3-
3ß, a duolink proximity ligation assay was applied to
GBM and astrocytoma sections. In all investigated
samples, hybridized and amplified antibody-linked
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Fig. 3. In situ hybridization of PTPIP51 in sections of human glioblastoma. A. Anti-sense probe. B. Sense probe of parallel section to A. C. Anti-sense
probe. D. Sense probe in parallel section to C. Arrows: PTPIP51 mRNA in glioblastoma cells, arrowhead: PTPIP51 mRNA in endothelial cells, double
arrow: immune cells, asterisk: necrotic tissue. Bar: 50 μm.
nucleotide strands were detected. Every dot corresponds
to an interaction between PTPIP51 and 14-3-3ß.
As seen in Figure 4G and H, glioblastoma and
astrocytoma cells displayed hybridized and amplified
antibody-linked nucleotide strands, revealing the in situ
interaction between PTPIP51 and 14-3-3ß.
GBM tumour cells situated around pseudo-
glomerular vessels, as well as endothelial cells and
immune cells, displayed a co-localization of PTPIP51
with PTP1B (Fig. 5A-C). To confirm an in situ
interaction of PTPIP51 and PTP1B, a duolink proximity
ligation assay was performed. As seen in Figure 5D
glioblastoma cells displayed hybridized and amplified
antibody-linked nucleotid strands, revealing the
interaction between PTPIP51 and PTP1B.
Raf-1 and PTPIP51 displayed a strong co-
localization in the vessels surrounding tumour cells (Fig.
6A-C).
There was only a partial co-localization of PTPIP51
and c-Src (Fig. 6D-F). In contrast to high PTPIP51
expression in the cytoplasm of tumour and immune cells
c-Src is only present in some of these cells. 
A majority of tumour cells displayed a co-
localization of PTPIP51 and EGFR (data not shown). 
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Fig. 4. PTPIP51 and its interacting partner 14-3-3ß - in situ co-localization analysis and Duolink proximity ligation assay in sections of human
glioblastoma and astrocytoma. A. PTPIP51 immunostaining GBM. B. 14-3-3ß immunostaining of section A. C. Merge of A and B. D. PTPIP51
immunostaining astrocytoma. E. 14-3-3ß immunostaining of section D. F. Merge of D and E. Arrows: PTPIP51 positive glioblastoma cells, arrowheads:
PTPIP51 positive endothelial cells, double-arrows: immune cells. G. GBM duolink proximity ligation assay for PTPIP51 and 14-3-3ß. H. astrocytoma
duolink proximity ligation assay for PTPIP51 and 14-3-3ß. Interaction of both proteins is seen as orange dots (arrows). I. Negative control. White
circles: lipofuscin granules. Bars: A-F, 50 μm; G-I, 10 μm.
Stained by Ki-67, proliferating cells showed a strong
expression of PTPIP51 in the cytoplasm with elevated
concentration near the plasmamembrane (Fig. 7A-C).
TUNEL assay analysis of GBM sections did not
show PTPIP51 positive cells executing apoptosis (Fig.
7D-F). 
mRNA expression of PTPIP51 and its interaction
partners
Qualitative reverse transcriptase PCR analysis: The
mRNA expression of PTPIP51 and its in vitro
interaction partners was tested by reverse transcriptase
PCR. As demonstrated in Figure 8, the samples 1, 2, 3
and 5 expressed a considerable amount of PTPIP51,
PTP1B, 14-3-3ß, Raf-1 and c-Src. A different expression
pattern was observed in sample number 4, which had
been obtained from a patient with a recurrent GBM. The
histopathological findings of this specimen showed
healthy cerebral tissue with only singular tumour cells.
In this case attenuated expression of PTPIP51 and
PTP1B was found, c-Src was barely detectable, and Raf-
1 was lacking (Fig. 8). 
Comparison of PTPIP51 expression levels in grade II
astrocytoma and glioblastoma by quantitative PCR
PTPIP51 expression levels of 5 GBM and 4 grade II
astrocytoma samples were assessed by quantitative PCR.
Candidate reference genes for normalization and the best
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Fig. 5. PTPIP51 and its interacting partner PTP1B in sections of human glioblastoma. A. PTPIP51 immunostaining. B. PTP1B immunostaining of
section A. C. Merge of section A and B. Arrows: PTPIP51 positive glioblastoma cells; Double arrows: immune cells. D. Duolink proximity ligation assay
for PTPIP51 and PTP1B. Interaction of both proteins is seen as orange dots (arrows). Bars: A-C, 20 μm; D, 10 μm.
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Fig. 7. PTPIP51 protein expression and investigation of proliferation and apoptosis by Ki67 antibody and TUNEL-assay. A. PTPIP51 immunostaining.
B. Ki67 immunostaining of section A. C. Merge of A and B. D. PTPIP51 immunostaining. E. TUNEL-assay of section D, insert: H.E. staining of detail 
F. Merge of D and E. Arrows: PTPIP51 positive glioblastoma cells, arrowheads: PTPIP51 positive endothelial cells, blank arrowhead: apoptotic
pericyte. Bar: 50 μm.
Fig. 6. PTPIP51 and its interacting partners Raf-1 and c-Src in sections of human glioblastoma. A. PTPIP51 immunostaining. B. Raf-1 immunostaining
of section A. C. Merge of A and B. D. PTPIP51 immunostaining. E. c-Src immunostaining of section D. F. Merge of D and E. Arrows: PTPIP51 positive
glioblastoma cells, arrowheads: PTPIP51 positive endothelial cells, double-arrows: immune cells. Bar: 50 μm.
combination of two genes were calculated according to
their expression stability by the NormFinder program.
The best fitting combination proved to be ß-actin with
GAPDH.
The results of expression analysis showed slightly
elevated levels of PTPIP51 (mean value 5.23±1.01) in
the group of GBM when compared to low grade
astrocytoma (mean value 4.62±1.49). 14-3-3ß expression
in glioblastoma (mean value 3.42±1.10) was
significantly higher than in grade II astrocytoma samples
(mean value 0.88±2.74) (Fig. 9).
Discussion
Our results revealed elevated levels of PTPIP51
expression in GBM (grade IV glioma) samples when
compared to low grade astrocytomas (grade II glioma),
which correlated with the expression levels of 14-3-3ß.
This is consistent with recent studies displaying a
tumour grade dependent expression of two isoforms of
14-3-3ß and 14-3-3η in gliomas. Healthy cerebral tissue
is completely lacking in both isoforms (Yang et al.,
2009). The upregulation of 14-3-3 proteins seems to be
associated with the reduced capacity of apoptosis, as
antagonizing 14-3-3 or silencing its expression induces
apoptosis in cultured glioma cells (Cao et al., 2010).
14-3-3ß and 14-3-3γ mediate the interaction of
PTPIP51 and Raf-1, thereby modulating the activity of
the MAPK-cascade (Lv et al., 2006; Yu et al., 2008;
Stenzinger et al., 2009). The MAPK pathway plays an
important role in cell migration and seems to be one of
the main reasons for recurrences and poor prognosis of
glioblastoma. It is considered that migrating tumour cells
infiltrate the healthy tissue surrounding the glioblastoma
and in this way can escape surgical extirpation and give
rise to regrowth. With regard to these findings the
interaction of PTPIP51 with 14-3-3ß, which was
confirmed by the duolink proximity ligation assay, may
mirror the role of PTPIP51 protein in migration and
proliferation of GBM tumour cells.
A strong co-localization and interaction of PTPIP51
and 14-3-3ß was also found in all endothelial cells of
GBM-typical glomerulum-like vessels of glioblastoma. 
This interaction may contribute to the well known
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Fig. 8. Expression of PTPIP51 and its interaction partners as detected
by reverse transcriptase-PCR in tissues of human glioblastoma.
Qualitative reverse transcriptase-PCR was performed using primers
specific to PTPIP51, PTP1B, Raf-1, c-Src and 14-3-3ß as given in
Materials and Methods section. ß-actin was amplified as an internal
positive control and probes lacking reverse transcriptase served as
negative controls (N).
Fig. 9. Quantitative real time PCR analysis of PTPIP51 and 14-3-3ß in
glioblastoma and grade II astrocytoma. A. Diagram shows the results of
quantitative expression analysis. Slightly elevated levels of PTPIP51 are seen
in the group of glioblastoma (GBM) when compared to low grade astrocytoma. 14-3-3ß expression in glioblastoma was significantly higher than in
grade II astrocytoma samples. Amplification of ß-actin and GAPDH was used as a combination of reference genes. B. Gel: bands exclusively detecting
mRNA with the expected amplification size with the primers used in 7A. Negative control (N).
high activation of the MAPK/Erk pathway via EGFR,
resulting in dysfunction of cell cycle control and
upregulation of proliferation in GBM. 
The non-transmembrane Protein Tyrosine
Phosphatase 1B (PTP1B), a known interacting partner of
PTPIP51, is able to activate the MAPK cascade on c-Src
and Ras level (Dubé et al., 2004; Dubé and Tremblay,
2004; Tonks and Muthuswamy, 2007; Zhao et al., 2008;
Stenzinger et al., 2009). Reichardt and coworkers (2003)
were unable to detect DNA amplification of PTP1B in
human gliomas. However, in our study PTP1B
expression was upregulated and highly co-localized with
the PTPIP51 protein. The observed upregulation is
consistent with the data reported by Akasaki and co-
workers (2006), who also reported PTP1B to be
overexpressed in gliomas. Furthermore, a direct in situ
interaction of PTPIP51 and PTP1B in glioblastoma cells
was corroborated by the duolink proximity ligation
assay. These results underline the significance of our
observations of upregulated PTPIP51 expression levels
in glioblastomas.
PTP1B contributes to oncogenesis by the loss of
tyrosine phosphorylation of key signalling proteins or by
up-regulation of two growth-promoting pathways
(Arias-Romero et al., 2009). In human mammary cells
PTP1B links an important oncogenic receptor tyrosine
kinase, namely ErbB2, to signalling pathways that
promote aberrant cell division and survival by activation
of Src and inducing a Src-dependent transformed
phenotype. It deactivates the Ras/MAPK pathway
inhibitor (Tonks and Muthuswamy, 2007).
C-Src mediates the phosphorylation of EGFR,
thereby promoting tumour progression (Tice et al.,
1999). The ultimate cellular response to the activation of
EGFR signalling cascade via MAPK pathway is DNA
synthesis and cell division (Halatsch et al., 2004). In our
samples PTPIP51 and EGFR were partly co-localized,
suggesting a synergistic effect on cell proliferation,
migration and oncogenic transformation. This may be
exerted by sharing the same final signalling pathway,
PTPIP51 via 14-3-3ß interaction with Raf-1 and EGFR
activating the Ras/Raf/MAPK/ERK pathway. Compared
to secondary GBM, developed by progression from
lower grade gliomas, EGFR gene amplification has been
shown to be five times higher in primary glioblastoma,
which leads to overexpression in 40% of GBM (Karpel-
Massler et al., 2009). Besides this EGFR overexpression,
EGFR is expressed as the mutated EGFRvIII (epidermal
growth factor receptor variant III) form of the receptor in
20% of GBM cases (Jutten et al., 2009). This
constitutively active mutant form of the EGFR, which is
commonly expressed in glioblastoma, is also detected in
a number of epithelial cancers (Yoshimoto et al., 2008;
Hama et al., 2009) also known to express high
concentrations of PTPIP51, e.g. non melanoma skin
cancer, prostate cancer (Koch et al., 2008; 2009b) and
breast cancer. EGFR signalling cascade via MAPK
pathway is modulated by PTP1B through c-Src and by
14-3-3ß through Raf-1 (Yu et al., 2008), both interaction
partners of PTPIP51. This in situ interaction in GBM
was substantiated in our study by duolink proximity
ligation assay (Gajadhar and Guha, 2010).
Glial malignant transformation might be correlated
to the status of PTPIP51 gene promotor methylation,
since high grade gliomas (GBM) also presented a higher
mRNA expression of PTPIP51 in comparison to low
grade gliomas (grade II astrocytoma). 
To sum up, in neuroepithelial tumours, PTPIP51
expression increases with the grade of malignancy and
PTPIP51 interacts in situ with 14-3-3ß and PTP1B. The
data presented in this study suggest an important role of
PTPIP51 in glioblastoma formation. 
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Abstract Protein tyrosine phosphatase interacting protein
51 (PTPIP51) is upregulated in glioblastoma multiforme
(GBM) and expression levels correlate with the grade of
malignancy in gliomas. A similar correlation was reported
for its interacting partner 14-3-3b, which has been shown
to facilitate the interaction of PTPIP51 with cRAF (Raf1).
Since the interaction of these signalling partners stimulates
growth factor signalling downstream of the epidermal
growth factor receptor (EGFR), a major drug target in
GBM, we here investigated the impact of EGFR inhibition
by small molecule inhibitors or monoclonal antibody on
PTPIP51. The effect of EGFR inhibition on PTPIP51
mRNA, protein expression and its interaction proﬁle in
GBM was analyzed using the U87 cell line as model sys-
tem. The transferability of the results to in vivo conditions
was evaluated in cultured tumour cells from GBM patients.
Cells were treated either to the small molecule tyrosine
kinase inhibitor of EGFR Geﬁtinib or the monoclonal an-
tibody Cetuximab in a time and dose dependent manner.
Geﬁtinib treatment decreased the proliferation rate and
induced apoptosis in U87 and primary tumour cells. The
PTPIP51 interaction proﬁle changed in correlation to the
applied Geﬁtinib. Despite unchanged mRNA levels
PTPIP51 protein was reduced. In contrast, treatment with
Cetuximab had no effects on PTPIP51 expression. In
conclusion, our results demonstrate the impact of EGFR
inhibition by Geﬁtinib on PTPIP51 protein expression, a
downstream regulator of MAPK signalling. These data will
serve as a basis to unravel the precise role of PTPIP51-
mediated signalling in GBM and its potential implications
for Geﬁtinib-mediated therapy in future studies.
Keywords PTPIP51  14-3-3b  Glioblastoma  EGFR 
Geﬁtinib  Cetuximab
Introduction
Despite powerful therapy regimens comprising neuro-
surgery, radiation and temozolomide, Glioblastoma (GBM)
is still one of the most lethal human cancers. Clinical trials
using EGFR targeting agents as mono therapy did not
generate promising results [1]. Current approaches are fo-
cusing on blocking the downstream EGFR-activated
metabolic pathways and their key kinase alterations [1].
Ampliﬁcation of the epidermal growth factor receptor
gene (ERBB2) is one of the most common oncogenic al-
terations in GBM (45 %), which leads to overexpression of
EGFR [2, 3]. Almost half of these cases co-express the
mutant receptor subtype EGFRvIII. This EGFR variant is
constitutively activated, and thereby may contribute to the
aggressive and refractory course of GBM, which is
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associated with a median survival of only 40 to 60 weeks
from diagnosis [4].
Therapeutic strategies targeting EGFR rely either on
tyrosine kinase inhibitors such as Geﬁtinib or on
monoclonal antibodies, e.g. Cetuximab. Thus, EGFR in-
hibition can be achieved by two different strategies: either
preventing ligand binding to the receptor or by directly
blocking the activity of the EGFR tyrosine kinase [5].
Cetuximab is a monoclonal antibody that targets the ex-
tracellular domain of EGFR thereby preventing the inter-
action with adequate ligands, and in turn intracellular
EGFR signalling. Besides, its direct effect on the MAPK
pathway, Cetuximab stimulates the internalization and
degradation of EGFR [5].
The small molecule inhibitor Geﬁtinib selectively in-
hibits tyrosine kinase activity of EGFR by binding to its
ATP-binding site and is currently approved as ﬁrst line
therapy in patients with non-small-cell lung cancer har-
boring activating epidermal growth factor receptor muta-
tion [6]. The efﬁcacy of Geﬁtinib-mediated EGFR-
inhibition in GBM is being evaluated in a clinical phase II
trial [7–9].
However, despite the fact that Geﬁtinib reaches high
concentrations in the tumour tissue, it does not seem to be
sufﬁcient to entirely shut down MAPK pathway activity
[10].
Clinical trials using EGFR inhibitors demonstrated only
modest improvements in a small percentage of GBM pa-
tients, suggesting that many GBMs possess primary in-
trinsic resistance mechanisms or rapidly acquire secondary
resistance to EGFR inhibition [11, 12].
Recently, we reported the expression of protein tyrosine
phosphatase interacting protein 51 (PTPIP51) in gliomas
and showed PTPIP51 expression levels to correlate with
the grade of tumour malignancy [2]. Interestingly, a similar
correlation was observed for its interacting partner 14-3-3b
[13, 14]. This direct interaction of PTPIP51 and 14-3-3
proteins was demonstrated in glioblastoma [2]. On the
molecular level, the interaction of PTPIP51 and 14-3-3b
leads to a ternary complex with cRAF (Raf1), which in turn
stimulates the downstream signalling of the EGFR/MAPK
signalling-pathway [15]. PTPIP51 interaction is regulated
by its Tyr176 phosphorylation in vitro and in situ at by Src
kinase and by its dephosphorylation through PTP1B [16].
Interestingly, both, the PTPIP51/14-3-3b and 14-3-3b/Raf1
interactions are inversely correlated with the PTPIP51
phosphorylation level [17]. Besides 14-3-3 mediated effect
of PTPIP51 on Raf1, PTPIP51 can directly interact with
EGFR [17, 18]. Taken together, these ﬁndings suggest a
functional role of PTPIP51 in the tumourigenesis of glio-
mas and glioblastomas in particular.
Since PTPIP51 is an important positive regulator of
EGFR downstream signalling at different levels, which
may contribute to mechanisms impairing the efﬁcacy of
therapeutic EGFR interference, we investigated the effect
of EGFR inhibition on PTPIP51 expression levels in U87
cells and primary GBM cell lines.
Materials and methods
Cell culture
The human glioblastoma cell line U87 (American Type
Culture Collection) and cell cultures from ﬁveGBMpatients
were kindly provided by the Neurosurgical-Neurooncologic
Laboratory, Justus-Liebig-University, Giessen, Germany.
The patients had given informed consent for research use of
the surplus material not used for pathology. The material
was obtained during neurosurgery and the cells were washed
in a solution of trypsin/medium 1:1 for 1 h and plated into
cell culture vials. They were cultivated in DMEM High
Glucose 4,5 g/l medium with 2-mmol/L glutamine supple-
mented with 10 % FCS and 1 x 105 IU/L penicillin, 100 mg/
l streptomycin until reaching a logarithmic growth phase
(less than three passages). Culture conditions were hu-
midiﬁed 5 % CO2 atmosphere and a temperature of 37 C.
When reaching near conﬂuency the cells were harvested by
adding 5 ml trypsin and 5 ml PBS (Dulbecco) and subse-
quently counted. Then the cells were resuspended in medi-
um into ﬂasks and part of them were seeded into
24-microwellplates for the evaluation of the metabolic rate
by the Alamar Blue test (AbD Serotec, BUF012B, UK). Part
of the cells were seeded on culture slides to perform im-
munoﬂuorescence analyzis after the experiments.
Inhibitors
All inhibitors were dissolved as stock solution in DMSO.
Prior to use they were diluted in DMEM. DMSO treated
cells were used as controls.
Geﬁtinib (#PKI-GFTB2-200, Biafﬁn, Kassel, Germany)
was applied in three different inhibitor concentrations 0.1,
1, 5 lM and for four different time periods (36, 48, 72,
96 h). The effects of the concentration gradient (0.1, 1, 2,
3, 4, 5 lM) of Geﬁtinib were analyzed after 24 h of in-
hibitor treatment by quantitative real time PCR.
Cetuximab (Erbitux, Merck) interacts exclusively with
domain III of soluble extracellular region of EGFR (S Li,
2005). It was applied in three different concentrations 2.5,
5, 10 lg/ml and for four different time periods (36, 48, 72,
96 h).
Erlotinib (LC Laboratories #E-4997) is a selective in-
hibitor of the tyrosine kinase domain of EGFR. It was
applied to glioblastoma cells in different concentrations
(0.1, 1, 10, 20 lM) for 24 h as well as 96 h.
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Metabolic rate evaluation
The Alamar Blue test (AbD Serotec, BUF012B, UK) was
performed in 24-well-plates. The test was applied to 20000,
10000, 5000 and 2500 cells, respectively. Alamar blue is a
nontoxic substrate for living cells giving a linear relation-
ship between the reduction of the blue substrate to a pink
product and the level of cell metabolism. After an incu-
bation of 36, 48, 72 and 96 h the remaining unmetabolized
blue substrate was determined photometrically by its ab-
sorption at 630 nm. Higher absorption values corresponded
to a reduced metabolic activity indicating cell death. The
metabolic rate was calculated and was correlated to the
internal standard (10,000 cells). The values were corrected
by subtracting the absorption of the negative control. Tests
with U87 cells for every inhibitor concentration for every
treatment time were repeated ﬁve times (n = 5). Hamid
et al. reported the Alamar blue test to be a more sensitive
proliferation assay than the well known MTT test [19].
Immunohistochemistry
The polyclonal antibody against PTPIP51 was raised as
described and characterized in previous studies [10, 13].
The speciﬁcity of the PTPIP51 antibody was tested by
ELISA and by immunoblotting of the isolated puriﬁed re-
combinant protein staining bands with 52, 34, and 30 kDa.
Immunoblotting of homogenates from porcine spleen tissue
revealed bands of 48, 40, and 29 kDa. The antibody binds
to the EGFP fusion PTPIP51 protein expressed in HEK293.
Preabsorbing the PTPIP51 antibody against its antigen
completely abolished the immune reaction in all tested
samples [15]. Double–immunostainings were performed
according to a standard protocol. After ﬁxation with
methanol for 2 min the slides were washed with phosphate
buffered saline (PBS, pH 7.4). The nonspeciﬁc binding
sites were blocked with 5 % bovine serum albumin and
5 % normal goat serum in PBS. Incubation with the pri-
mary antibodies (PTPIP51 = rabbit polyclonal, 1:400 di-
lution, generated by Prof. H W Hofer, Biochemical
Department, University Konstanz, Germany; 14-3-
3b = mouse monoclonal, 1:100 dilution, from Santa Cruz,
Cat #sc-25276) was performed overnight at room tem-
perature, followed by the incubation for 1 h with the ap-
propriate secondary antibodies (Alexa ﬂuor 488 coupled to
anti-mouse antibody, Invitrogen Cat #A11029 and Alexa
ﬂuor 555 coupled to anti-rabbit antibody, Invitrogen Cat
#A21428) at room temperature. Subsequently the slides
were coverslipped in carbonate buffered glycerol (pH 8.6).
Nuclei were visualized by DAPI. For each staining series
appropriate controls were performed. The results were vi-
sualized using an excitation ﬁlter of 530 - 560 nm wave
length (Alexa ﬂuor 555) and an emission ﬁlter with a range
572.5–647 nm wavelength. Alexa ﬂuor 488 was visualized
by an excitation ﬁlter with 460–500 nm wave length and an
emission ﬁlter 512–542 nm wavelength. Immunoﬂuores-
cence analysis and photo-documentation was performed
with an Axioplan 2 ﬂuorescence microscope equipped with
Plan-Apochromat objectives (Carl Zeiss Jena, Germany).
Quantitative real time PCR
Cells were harvested by trypsination and transferred into
RNA later (Qiagen) for storage at -20 C. cDNA ampliﬁ-
cation was performed in 25 ll reaction volume on the iCy-
cler iQReal-Time PCRDetection System (BioRad,Munich,
Germany). Primers were chosen as described previously [2].
The ﬁnal reaction tube contained 100nM as PTPIP51, 14-3-
3b and reference genes b-actin and GAPDH, 12.5 ll iQ
SYBRGreen Supermix (BioRad) and 2 ll ofDNA template.
The PCR conditions were 94 C for 3 min followed by 40
cycles for 30 s, 60 C for 30 s and 72 C for 1 min. Melting
curves were generated for both genes after ampliﬁcation.
Negative controls were included in each run. The appropriate
combinations of reference genes for the expression analysis
of PTPIP51 and 14-3-3b in U87 and primary GBM cells,
were selected by the NormFinder Program.
Statistical analyses: In U87 cells the examination of
every inhibitor concentration at every treatment time was
repeated ﬁve times (n = 5). The values were subsequently
analyzed by GraphPad Software (San Diego, California)
version 6.00 using the Dunnett’s multiple comparison test.
Results were considered as signiﬁcant with p\ 0.05.
Analysis of the EGFR status
U87 Cells and the ﬁve primary cell cultures were analyzed
for mutations in EGFR (exons 1, 8 and 18–21) by Sanger
sequencing. Extraction of genomic DNA was performed by
proteinase K digestion using a fully automated puriﬁcation
system (QIASymphony SP; Qiagen, Hilden, Germany).
DNA content was measured using a spectrophotometer
(NanoDrop; Thermo Scientiﬁc, Wilmington, DE, USA). For
PCR ampliﬁcation the following primers were used. EGFR:
50-agcgctcctggcgctgc-30 (exon 1), 50-acttgcggacgccgtcttcc-
30 (exon 8), 50-gctgaggtgacccttgtctc-30 (exon 18 forward),
50-acagcttgcaaggactctgg-30 (exon 18 reverse); 50-gctggtaa
catccacccaga-30 (exon 19 forward), 50-gagaaaaggtgggcct
gag-30 (exon 19 reverse); 50-catgtgcccctccttctg-30 (exon 20
forward), 50-gatcctggctccttatctcc-30 (exon 20 reverse);
50- cagagcttcttcccatgatga-30 (exon 21 forward), 50-cctggt
gtcaggaaaatgct-30 (exon 21 reverse). Direct sequencing of
the PCR amplicons was performed for both strands on a
3500 Genetic Analyzer using the BigDye Terminator v1.1
Cycle Sequencing Kit (both Applied Biosystems, Life
Technologies, Carlsbad, CA, USA).
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Immunoblotting
Immunoblot samples of GBM cell lysates were separated on
a NuPAGENovex 4–12 % Bis–Tris Gel (Life Technologies
GmbH, Darmstadt, Germany Cat #NP0329BOX). Transfer
on an Immobilon P membrane (Millipore, Billerica, USA,
Cat #IPVH07850) was performed according to Towbin et al.
[20]. The membrane was blocked with 1 9 Rotiblock for
1 h at room temperature. Incubation with monoclonal rabbit
anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)
(D13.14.4E) XP (Cell Signalling #4370), monoclonal
rabbit anti-total p44/42 MAPK (Erk1/2) (137F5) (Cell Sig-
nalling Cat #4695), polyclonal rabbit anti-PTPIP51 (Prof.
HWHofer, Biochemical, Department, University Konstanz,
Germany), polyclonal guinea pig anti-phosphoTyr176-
PTPIP51 (BioLux, Stuttgart, Germany) and anti-beta actin
(Cell Signalling Cat #4967) was done overnight at 4 C.
HRP-conjugated anti-guinea pig or HRP-conjugated anti-
rabbit immunoglobulins were applied for 1 h at room tem-
perature diluted in 1 9 Rotiblock. The reaction was visu-
alized with the ECL prime substrate. For documentation an
Amersham Hyperﬁlm ECL (GE Healthcare Lifescience,
Freiburg, Germany, Cat #28-9068-36) was used. Calibration
was performed with a molecular weight marker suitable for
chemiluminescence (Life Technologies GmbH, Darmstadt,
Germany, Cat #LC5602).
Duolink II proximity ligation assay (DPLA)
The downstream effects on the in situ interactions were
detected by the proximity ligation assay kit Duolink II
(Olink Bioscience, Uppsala, Sweden; PLA probe anti-
rabbit minus, Cat #92005-0100; PLA probe anti-mouse
plus, Cat #92001-0100; Detection Kit Orange, Cat #92007-
0100). The DPLA probe anti-rabbit minus binds to the
PTPIP51 antibody, whereas the PLA probe anti-mouse plus
binds to the antibody of 14-3-3b, pErk, Raf1 and PTP1B.
The DPLA secondary antibodies only generate a signal
when the two DPLA probes have bound, which only takes
place if both the proteins are closer than 40 nm, indicating
their interaction. PFA-ﬁxed U87 cells were preincubated
with blocking agent for 1 h. After washing in PBS for
10 min, primary PTPIP51 antibody (1:1000) was applied to
the samples. Primary antibodies of the interacting partners
were used for proving the interaction by co-incubation with
the PTPIP51 antibody. Incubation was done overnight in a
preheated humidity chamber. Culture slides were washed
three times in PBS for 10 min. DPLA probes detecting
rabbit or mouse antibodies were diluted in the blocking
agent in a concentration of 1:5 and applied to the slides
followed by incubation for 1 h in a preheated humidity
chamber at 37 C. Unbound DPLA probes were removed
by washing twice in PBS for 5 min. The samples were
incubated with the ligation solution consisting of Duolink
II ligation stock (1:5) and Duolink ligase (1:40) diluted in
high purity water for 30 min at 37 C. After ligation, the
Duolink ampliﬁcation and detection stock, diluted 1:5 with
addition of polymerase (1:80), was applied to the slides for
100 min. Dapi was used to identify the nuclei. After the
ﬁnal washing steps, the slides were dried and cover slips
were applied.Quantiﬁcation was done with the Duolink
Image Tool (Olink Bioscience, Uppsala, Sweden,
v1.0.1.2). The signal threshold was adjusted to 135 and
pixel size for spot detection to ﬁve pixels for each picture.
The quantiﬁed DPLA spots were calculated per cell
(number of dots/cell) for each picture.
Statistical analyses: The quantiﬁed DPLA spots were
calculated per cell (number of dots/cell) for each picture.
The results were standardized to the number of interac-
tions/100 cells. The values were subsequently analyzed by
GraphPad Software (San Diego, California) version 6.00
using the Dunnett’s multiple comparison test. Results were
considered as signiﬁcant with p\ 0.05.
Results
Cellular vitality under Cetuximab treatment
Treatment of U87 cells either with 2.5, 5 or 10 lg/ml
Cetuximab for 36 h had no effect on the number of cells
compared to the controls. 48 h of treatment with 2.5, 5 or
10 lg/ml Cetuximab did not change the number of cells
compared to controls. Application of 2.5, 5 or 10 lg/ml
Cetuximab for either for 72 or 96 h had no effect on the
number of cells compared to controls (Fig. 1a). The same
hold true for all primary cell cultures (Supplement A1 A).
Cellular vitality under Geﬁtinib treatment
Treatment of U87 cells either with 0.1, 1 and 5 lM Geﬁ-
tinib for 36 h reduced the cell number in a concentration
dependent manner (Fig. 1b). For each concentration these
reductions in cell number were statistically signiﬁcant in
comparison to the control. 48 h of treatment with 0.1, 1 and
5 lM Geﬁtinib signiﬁcantly reduced the number of cells in
a concentration dependent manner compared to controls.
Application of 0.1, 1 and 5 lM Geﬁtinib either for 72 or
96 h had the same statistically signiﬁcant concentration
dependent effect on the number of cells compared to
controls. Treatment with 5 lM Geﬁtinib resulted in an
almost complete reduction of viable cells at every time of
incubation (Fig. 1b). The same hold true for all primary
cell cultures (Supplement A1 B).
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Cellular metabolism under Cetuximab treatment
Treating U87 cells with 2.5, 5 or 10 lg/ml Cetuximab for
36 h had no signiﬁcant effect on cellular metabolism
compared to controls as tested by Alamarblue. This indi-
cates high normal cell vitality as seen in Fig. 2a. Control
values correspond to 100 %. The values of treated cells are
given in percent of the control value (Fig. 2a). Prolonging
the incubation time to 48, 72 or 96 h had no signiﬁcant
effect on cell viability neither under the inﬂuence of 2.5, 5
or 10 lg/ml Cetuximab in relation to the controls.
Cellular metabolism under Geﬁtinib treatment
As tested by Almarblue, treating U87 cells with 0.1, 1 and
5 lM Geﬁtinib for 36 h reduced cellular metabolism in a
strictly concentration dependent manner in relation to
controls. This indicates a reduced cell vitality as seen in
Fig. 2b. Control values correspond to 100 %. The values of
treated cells are given in percent of the control value.
Prolonging the incubation time to 48 and 72 h also let to a
concentration dependent reduction of cell vitality the
magnitude of which was the same as seen after 36 h. In-
cubating the cells for 96 h with 0.1, 1 and 5 lM Geﬁtinib
reduced cell viability in a concentration dependent manner.
The reduction of cell vitality after 96 h incubation with the
5 lM Geﬁtinib was signiﬁcant.
Protein expression
Immunoﬂuorescence assays of PTPIP51 and 14-3-3b pro-
tein in U87 cells (Fig. 3) displayed high levels of both
proteins in the control group. High concentrations of
PTPIP51 were seen perinuclear area and granules of the
protein at the cell membrane (Fig. 3a). 14-3-3b displayed
an evenly cytoplasmic distribution (Fig. 3b). Both proteins
were partially colocalized (Fig. 3c).
Treatment with 10 lg/ml Cetuximab for 72 h did not
alter the PTPIP51 and 14-3-3b protein expression (Fig. 3d,
e) compared to control cells (Fig. 3a, b). The subcellular
distribution of both proteins remained the same. A partial
cololalization of both proteins was displayed in Cetuximab
treated cells comparable to the controls (Fig. 3f).
Application of 5 lM Geﬁtinib for 72 h resulted in a
pronounced reduction of PTPIP51 as well as 14-3-3b
Fig. 1 Cell proliferation. a Cetuximab: Number of cells after 36, 48,
72 and 96 h after adding Cetuximab in following concentrations: IC1
(2,5 lg/ml), IC2 (5 lg/ml) and IC3 (10 lg/ml). Every group started
with 500,000 cells. Application of the monoclonal antibody to EGFR
Cetuximab did not lead to a reduction in cell numbers independent of
the applied concentration or incubation time in the ﬁve probed
primary cultures. Only in U87 (N = 5) there was a slight decrease of
inhibited cells compared to the reference group after 96 h (Fig. 2b).
b Geﬁtinib: Number of cells after 36, 48, 72 and 96 h after adding
Geﬁtinb. Every group started with 500,000 cells. The not inhibited
reference group reached a higher amount of cell number than the
others at every time. The number of treated cells was negatively
correlated to the applied inhibitor concentration for 0.1 and 1 lM
being the result of a reduced proliferation rate compared to the
reference group. Application of 5 lM Geﬁtinib led to a decreased
number of cells, which cannot be explained by complete inhibited
proliferation alone. Values were analyzed by using the Dunnett’s
multiple comparison test. *p\ 0.05, **p\ 0.01 and ***p\ 0.001
Fig. 2 Cell metabolism. b Geﬁtinib: Metabolic rates were reduced in
a dose dependent manner by the application of 1 (IC2) and 5 lM
(IC3) Geﬁtinib. Concentration of 0.1 lM (IC1) Geﬁtinib had no effect
on the metabolic rate. Only the IC3 group displayed a time dependent
decrease in the metabolic rate. a Cetuximab: Inhibtion with IC1
(2.5 lg/ml), IC2 (5 lg/ml) and IC3 (10 lg/ml) Cetuximab led to a
marginal reduction in the metabolic rate in a dose dependent matter.
This reduction was independent from the application time. Control
values represent 100 %
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protein (Fig. 3g, h). PTPIP51 changed its subcellular dis-
tribution to a highly granulated form. The same applied to
14-3-3b protein. Three out of ﬁve cells in the Fig. 3g, h
revealed limited or even nonexistent of PTPIP51 and 14-3-
3b. As shown in the merge (Fig. 3i) the remaining proteins
are partial colocalized. The nuclei of the Geﬁtinib treated
cells reveal signs of fragmentation as indication for apop-
tosis (Fig. 3i).
Quantitative mRNA of PTPIP51 and 14-3-3
under Cetuximab treatment
Submitting U87 cells to increasing concentrations of Ce-
tuximab (2.5, 5, 10 lg/ml) for 24 h did neither change
PTPIP51 expression nor 14-3-3 expression (Fig. 4a) com-
pared to the expression of the expression seen for controls
(Fig. 4a). Prolongation of the incubation time to 48, 72 or
96 h had no effect on the mRNA expression (Fig. 4a) of
PTIP51 and 14-3-3 protein. As seen in cells treated for 24 h
increasing Cetuximab concentrations from 2.5 to 5 lg/ml
or 10 lg/ml also did not inﬂuence the mRNA levels of
PTPIP51 and 14-3-3 protein (Fig. 4a).
Quantitative mRNA of PTPIP51 and 14-3-3
under Geﬁtinib treatment
Submitting U87 cells to increasing concentrations of Ge-
ﬁtinib (0.1, 1 and 5 lM) for 24 h had no signiﬁcant effect
on PTPIP51 and 14-3-3 expression compared to the ex-
pression of PTPIP51 and 14-3-3b in control cells (Fig. 4b).
Application of 0.1, 1 and 5 lM Geﬁtinib for 48 h to U87
cells had no signiﬁcant effect on the expression of PTPIP51
and 14-3-3 mRNA levels in comparison to the mRNA
levels seen in controls. Even after 72 and 96 h there were
Fig. 3 Double immunostaining of protein expression. Staining of
PTPIP51 and 14-3-3b in U87 cells. Untreated tumour cells (control)
show high concentrations of PTPIP51 (a) and 14-3-3b (b) which are
colocalized as shown in the merge picture (c) and highly expressed in
the cytoplasm of tumour cells. In contrast to the control (a–c) and the
Cetuximab treated cells (d–f), Geﬁtinib treated cells had lower levels
of PTPIP51 (g) and 14-3-3b (h). The nuclei are additional shown by
DAPI in the merged photographies (c, f, i). In i is a less number of
cells compared to c and f, which was already explored by the
proliferation rates. Treating U87 cells with Cetuximab did not alter
the PTPIP51 expression pattern compared to untreated cells (g, h).
Bar = 20 lm
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no signiﬁcant differences in mRNA expression levels of
(Fig. 4b). Likewise, there were no signiﬁcant differences of
the mRNS expression levels of PTPIP51 and 14-3-3 protein
compared to the values seen in controls in the primary cell
cultures (Supplement A4).
Interaction proﬁle of PTPIP51 under Geﬁtinib
treatment
The interaction proﬁle of PTPIP51 with selected partners
was assessed by the Duolink proximity ligation assay.
Fig. 4 Quantitative RT PCR of PTPIP51 and 14-3-3 mRNA. a Quan-
titative PCR of Cetuximab treated U87 cells: No signiﬁcant differences
in PTPIP51 and 14-3-3mRNAwere seen after 24 h (upper left panel) of
treatment with 2.5, 5 and 10 lg/ml Cetuximab compared to controls.
Likewise no signiﬁcant differences in both proteins mRNA were
detected after incubation periods of 48 h (upper right panel), 72 h
(lower left panel) and 96 h (lower right panel). b Quantitative PCR of
Geﬁtinib treated U87 cells: No signiﬁcant differences in PTPIP51 and
14-3-3 mRNAwere seen after 24 h (upper left panel) of treatment with
0.1, 1 and 5 lMGeﬁtinib compared to controls. Likewise no signiﬁcant
differences in both proteins mRNA were detected after incubation
periods of 48 h (upper right panel), 72 h (lower left panel) and 96 h
(lower right panel). Values were analyzed by using the Dunnett’s
multiple comparison test
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Treating U87 cells with 1 and 5 lM Geﬁtinib for 24 h
signiﬁcantly reduced the interaction with 14-3-3b protein.
The number of interactions was reduced by about 50 %
under either concentration (Fig. 5a). Treating U87 cells
with 1 lM and 5 lM Geﬁtinib for 48 h signiﬁcantly in-
creased the number of interactions with 14-3-3b protein by
about 87 and 84 % respectively (Fig. 5a).
The interaction with Raf1 was affected in a comparable
way. One lM Geﬁtinib reduced the interactions by 50 %
whereas 5 mM Geﬁtinib reduced the number of interac-
tions by about 40 % after 24 h of incubation. After 48 h the
number of interactions with Raf1 was reduced by 50 and
58 %, respectively (Fig. 5a).
The interaction of PTPIP51 with pERK slightly in-
creased under the inﬂuence of 1 lM Geﬁtinib (?17 %),
whereas 5 lM Geﬁtinib resulted in a signiﬁcant reduction
in the number of interactions (about 50 %) after 24 h of
treatment. After 48 h of incubation the number of
interactions of PTPIP51 with pERK in U87 cells decreased
by the application of 1 lM Geﬁtinib. Treating the cells
with 5 lM Geﬁtinib for 48 h slightly increased the number
of interactions by about 6 %. Under these conditions the
number of interactions of PTPIP51 with PTP1B was re-
duced by 44 %. (Figure 5a).
After 24 h of 5 lM Geﬁtinib exposure the interaction
proﬁle of PTPIP51 with PTP1B revealed any differences
compared to the number of interactions in control group.
The number of interactions between PTPIP51 and PTP1B
decreased signiﬁcantly after 48 h of incubation by 5 lM
Geﬁtinib (Fig. 5b).
Immunoblot
Cells treated either with 1 and 5 lM of Geﬁtinib for 24 h
displayed tendending reduced PTPIP51 protein as dis-
played in the immune blot (Fig. 5b). An incubation period
Fig. 5 Interaction proﬁle and downstream effects. a Interaction
proﬁle of PTPIP51 with 14-3-3b, pErk and Raf1 in 1 and 5 lM
Geﬁtinib treated U87 cells after 24 and 48 h of incubation. After 24 h
treatment the interactions of PTPIP51 with 14-3-3b were markedly
reduced in both Geﬁtinib concentrations (1 and 5 lM) to the same
extent. After 48 h both concentrations of Geﬁtinib (1 and 5 lM)
treatment led to an increased number of interactions of PTPIP51 with
14-3-3b compared to control. After 24 h treatment the interactions of
PTPIP51 with pErk were only reduced by 5 lM Geﬁtinib. After 48 h
only 1 lM Geﬁtinib negatively affected the number of interactions.
After 24 h treatment the interactions of PTPIP51 with Raf1 were
reduced in both Geﬁtinib concentrations (1 and 5 lM). After 48 h
both concentrations of Geﬁtinib (1 and 5 lM) treatment led to a
decreased number of interactions of PTPIP51 with Raf1. Immunoblot
analyses of phopsphorylated Erk1/2 and total Erk1/2 in control cells
(C) and cells treated with 1 lM Geﬁtinib (G1), 5 lM Geﬁtinib (G2),
5 lg/ml Cetuximab (C1) or 10 lg/ml Cetuximab (C2) are shown
either for 24 or 48 h. The downstream effect of EGFR inhibition by 1
(G1) and 5 lM Geﬁtinib (G2) resulted in reduced phosphorylated
Erk1/2 after 24 h as well as after 48 h. The total Erk1/2 displayed any
difference in Geﬁtinib treated compared to the control. b-actin was
used for standardization. b Interaction proﬁle of PTPIP51 with PTP1B
in 5 lM Geﬁtinib treated U87 cells after 24 and 48 h of incubation.
There were no differences in the number of interactions per 100 cells
between control and Geﬁtinib treated cells after 24 h. 48 h of
Geﬁtinib treatment markedly reduced the interactions of PTPIP51 and
PTP1B compared to control. Values were analyzed by using the
Dunnett’s multiple comparison test. *p\ 0.05, **p\ 0.01 and
***p\ 0.001. Upper panel: Immunoblot analyses of total PTPIP51
in control cells (C) and in cells treated with 1 lM Geﬁtinib (G1),
5 lM Geﬁtinib (G2), 5 lg/ml Cetuximab (C1) or 10 lg/ml Cetux-
imab (C2) either for 24 h or 48 h. Lower panel: Immunoblot analyses
of tyrosine 176 phosphorylated PTPIP51 in control cells (C) and in
cells treated with 1 lM Geﬁtinib (G1), 5 lM Geﬁtinib (G2), 5 lg/ml
Cetuximab (C1) or 10 lg/ml Cetuximab (C2) either for 24 or 48 h. b-
actin was used for standardization
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of 48 h led to a further reduction in the PTPIP51 protein.
Both concentrations of Geﬁtinib lowered the fraction of
tyrosine 176 phosphorylated PTPIP51 independent of the
incubation time.
The downstream effect of EGFR inhibition by 1 and
5 lM Geﬁtinib resulted in reduced phosphorylated Erk1/2
after 24 h as well as after 48 h. The total Erk1/2 displayed
any difference in Geﬁtinib treated compared to the control
(Fig. 5a).
EGF receptor proﬁle
U87 cell line as well as the primary cell cultures used for
this study displayed the full length transcript for Wildtype
EGFR from exon 1 to 8. Additional analysis of possible
mutations in the exons 18-21 displayed no cell culture with
a mutated EGFR.
Erlotinib
Additionally, we investigated Erlotinib incubation of U87
cell by in increasing concentrations (1 and 20 lM) for in-
creasing times (24, 96 h) by immnostaining as shown in
supplements. Like Geﬁtinib, Erlotinib targets the EGFR
tyrosine kinase by reversible binding to the ATP binding site
of the receptor. The application of 1 lM Erlotinib for 24 h
resulted in dispersed granular cytoplasmic distribution of
PTPIP51. After 96 h treatment with 1 lM Erlotinib a more
attenuated granular pattern of the reduced PTPIP51 protein
(A3B) was seen. The application of 20 lM Erlotinib re-
sulted in a distinct subcellular localization of PTPIP51 with
highest concentrations in the perinuclear region (A3 C and
F). With increasing incubation time (96 h) 20 lM Erlotinib
treatment resulted in a further redistribution of PTPIP51 to a
dispersed granular pattern (A3 D).
Discussion
The epidermal growth factor receptor pathway is probably
the most signiﬁcant signalling pathway in glioma, which
successfully can be exploited clinically [21, 22]. About
30 % of GBM reveal this speciﬁc EGFR mutation. This
mutation leads to the loss of exons 2–7 coding for part of
the extracellular domain and a constitutively enhanced
EGF signalling promoting tumour growth [23]. As shown,
the primary glioblastoma cells as well as the U87 cell line
displayed wt alleles of EGFR. Nevertheless, these cells
displayed aggressive growth behaviour accompanied by
enhanced EGFR signalling. The EGFR is linked to a va-
riety of downstream signalling molecules, such as the Ras/
Raf/MEK/Erk cascade [24]. This MAPK pathway is
essential for proliferation and cell division, all hallmarks of
the malignant nature of glioma cells [3, 4]. The MAPK
pathway activity is tightly regulated by subsequent serine
phosphorylation of the signalling molecules [24]. In addi-
tion, several modulating molecules bind to speciﬁc targets
of the MAPK pathway, for example the Raf1 kinase in-
hibitor protein (RKIP), which in turn binds to Raf1 to in-
hibit the MAPK pathway at the Raf1 level [25]. Here,
RKIP tightly regulates Raf1 during mitosis, which titrates
the signal of the MAPK pathway ensuring normal cell di-
vision, essential for tumour cell growth. A recent study
identiﬁed RKIP to inhibit cell growth in glioma cells [25].
Of note, PTPIP51 acts also on Raf1 level as an activator
of the MAPK pathway. Furthermore, PTPIP51 interacts
with the main receptor tyrosine kinase of the MAPK
pathway, namely the EGFR. PTPIP51 interactions are
regulated by its tyrosine phosphorylation status [17]. The
phosphorylation status affects the Raf1 binding ability as
well as the interaction of PTPIP51 with its linker protein
14-3-3. The active EGFR is capable to phosphorylate
PTPIP51 at tyrosine 176 residue and therefore preventing
the Raf1 activation induced by PTPIP51. Treating a human
keratinocyte cell line (HaCaT) with Geﬁtinib resulted in an
increase of the PTPIP51/Raf-1 and PTPIP51/14-3-3 inter-
actions [17]. Administrating the epidermal growth factor
(EGF) to the cell line resulted in a sharp drop of both
interactions. Interestingly, long-time exposition of HaCaT
cells to EGF induced a decrease in the overall mRNA level
of PTPIP51 [15].
Treating glioma cells with Geﬁtinib the tyrosine 176
phosphorylation of PTPIP51 was slightly reduced after 24
and 48 h. In contrast to results obtained in the HaCaT cell
line the interaction of PTPIP51/14-3-3 and PTPIP51/Raf1
was reduced in GBM cells. The lowered activation of
Erk1/2 reﬂects the decreased interaction of PTPIP51 with
Raf1. Notably, there was still a basal level of MAPK
activation of Geﬁtinib exposed cells as seen by
immunoblotting. These observations may be explained by
increased activity of Src kinase family members linked to
alterations of glioblastoma cells [26, 27]. As reported by
Du and coworkers, Src is frequently activated in human
GBM lines and primary tumours [27]. The c-Src activation
of EGFR results in the basal MAPK pathway activity and
the basal level of tyrosine 176 phosphorylation of PTPI51.
Interstingly, after 24 h Geﬁtinib incubation there was no
counter-regulation of this tyrosine 176 phosphorylation by
PTP1B. Moreover, c-Src is also capable of phosphorylating
tyrosine 176 residue of PTPIP51 and preventing Raf1
activation [16]. After 48 h of Geﬁtinib incubation the
PTPIP51/PTP1B interaction was additionally decreased.
Interestingly, the PTPIP51/14-3-3 was increased analogue
to the effect in the HaCaT cell line as a compensatory
mechanism, whereas the Raf1 interaction level remained
low [28]. These observations also resemble the known high
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activity of c-Src and the accompanying low PTP1B inter-
action inhibiting PTPIP51 to interact with Raf1 [26].
Higher levels of the phosphorylated Erk1/2 in glioblas-
toma activate MAPK [29]. This leads to a variety of tran-
scription factor activations in the nucleus, such as c-myc
activated by Erk1/2. Interestingly, there is an inherent c-myc
binding site in the PTPI51 promoter as annotated in the
USCS genome browser (http://genome-euro.ucsc.edu/cgi-
bin/hgc?hgsid=201968018_OSKna1QFaHG9YIz0kDpv5Q
tlJoF1&c=chr15&o=41047249&t=41047699&g=wgEncod
eRegTfbsClusteredV3&i=MYC). Therefore, the elevated
Erk1/2 probably inhibits a sharp decrease in PTPIP51
mRNA. The long-time adaptation of PTPIP51 protein
expression does not work in contrast to the observations
made on the HaCaT cell line [14, 25]. Additionally similar
results were proved in a phase II trial of Geﬁtinib in glio-
blastoma hinting to a regulation of downstream signal
transducers in the EGFR pathway probably dominated by
regulatory circuits independent of EGFR phosphorylation
[8, 10]. This argues for the development of resistance against
Geﬁtinib therapy, which has already been observed in lung
cancer [30].
To investigate another inhibitory mechanism a mono-
clocal antibody to EGFR (Cetuximab) was used. The
monoclonal antibody Cetuximab neither effected tumour
cell proliferation nor PTPIP51 and 14-3-3b mRNA and
protein expression. Comparable failure of action was seen
in clinical trials with GBM patients [27, 31, 32], despite
successful clinical use in patients suffering from lung,
colorectal and head and neck cancers [5, 33, 34]. The lack
of response to Cetuximab treatment may be due to
heterodimerization of the EGFR with Her2 (Erb2), to
c-Met/HGF or activation IGF-1R activation [35]. A study
by Clark et al. revealed the circumvention of EGFR inhi-
bition by turning on two other EGFR family receptors
(ERBB2 and ERBB3) in cancer stem cells, which contin-
ued to grow [11]. Activation of ERBB2 signalling in cell
lines, either through ERBB2 ampliﬁcation or through
heregulin up-regulation leads to a permanent ERK1/2 sig-
nalling essentially resulting in resistance to Cetuximab-
mediated inhibition of the EGFR [23]. In addition,
glioblastomas expressing wt EGFR –as in the employed
cell lines of this work- are less sensitive to treatments in
combination with Cetuximab [36].
To conclude, PTPIP51 was identiﬁed to be involved in
the EGFR/MAPK pathway in glioblastoma cells. This
indicates a possible therapeutic target to resistance
mechansims in anti-EGFR therapy by Geﬁtinib. Further
studies are needed to investigate the potential of interfer-
ence in the EGFR phosphorylation independent regulatory
circuits, in order to make the MAPkinase pathway sensitive
for the knock down of PTPIP51.
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